2008 LLS Annual Report

2008 Annual Report

The Leukemia & Lymphoma Society is a nonproﬁ t organization that relies on the generosity of individual, foundation and corporate contributions to advance its mission.

The NEED for SPEED

1311 Mamaroneck Avenue • Suite 310 White Plains, NY 10605 914.949.5213 www.lls.org

P001 20M 12/08

0814172_cover.indd 1-2 11/17/08 7:23:42 PM Our MISSION Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

0814172_cover.indd 3-4 11/17/08 7:23:43 PM Our VISION By 2015, the vast majority of people diagnosed with a blood cancer will be cured or will manage their illness with good quality of life. The Leukemia & Lymphoma Society North Star 2015 Vision

0814172_01_13.indd 1 11/17/08 6:16:11 PM 2

President & Chairman’s MESSAGE

John E. Walter President and CEO

When The Leukemia & Lymphoma Society (LLS) conceived a world that would transform the lives of patients with blood cancer – a world that would exist as soon as 2015 – we knew the realization of this ambitious vision would require a cultural transformation. We conceived new strategies for every level of LLS to help advance our North Star 2015 Vision; in 2008, those strategies began to come to life. This year’s annual report will highlight just one of the many changes to the way we do business, which will help us get more therapies to more patients, faster: our Therapy Acceleration Program. The Therapy Acceleration Program takes a different approach to moving blood cancer research through the development process. The pharmaceutical company model for developing new cancer treatments favors research with high odds of producing blockbuster drugs and proﬁ ts based on high demand. Blood cancers have a low incidence relative to solid tumors, heart disease and other widespread health issues. So under the pharma model, too many projects that might produce new treatments for blood cancer patients instead sit in the pipeline, undeveloped. And that is unacceptable, because with development, one or more of those projects could be the next major treatment advance or even cure. As you read more about the Therapy Acceleration Program

0814172_01_13-03.indd 2 11/20/08 5:17:47 PM 3 Society Lymphoma & Leukemia The

David Frantze Chair

in this report, you’ll understand how the program will help speed discoveries from laboratories into new therapies for patients. We believe the Therapy Acceleration Program is a bold move in the right direction. Other positive steps this year included a revitalized sponsorship program that is already providing results, the continued strength of our major fundraising campaigns and a major advance for LLS into emerging technologies that will help us communicate more effectively with our constituents. This last project includes an increase in the Google grant for search-engine marketing, which already generates nearly half of all trafﬁ c to the LLS Web sites. Progress was also made in our important initiative to get more patients into clinical trials, including a partnership with the Coalition of Cancer Cooperative Groups that resulted in the launch of TrialCheck ®, a clinical trial search tool, at www.LLS.org. Fiscal year 2008 was not without challenges for LLS. Change is rarely easy. But the organization’s reaction was to “rise up and meet the challenges.” In the end, it was an incredibly productive year, one in which large strides were made toward achieving the North Star Vision – toward cures for blood cancers.

0814172_01_13-03.indd 3 11/20/08 5:17:51 PM 4

SPEED Saves Lives

One million North Americans and their families are living with blood cancer. Approximately 135,000 more will be diagnosed in 2008. And nearly half of these newly diagnosed patients are expected to die within ﬁ ve years. In the face of these numbers, a successful drug can have a major impact on people’s lives.

But the traditional process for drug development is not encouraging for new blood cancer discoveries. Because of their low incidence relative to solid tumors, heart disease and other widespread health issues, individual blood cancers are considered “orphan diseases.” The development of blood cancer treatments is often delayed in favor of projects with higher revenue potential. New discoveries become “bottlenecked” and, as time goes by, lives that might have been saved are lost.

A research discovery ﬁ rst known as STI-571 tells the story well. This was a chemical in a pharmaceutical company pipeline in the 1990s, with no immediate plans for development as an anti-cancer drug. It might have stayed on the shelf indeﬁ nitely if LLS funding to researcher Brian Druker, M.D., hadn’t accelerated its development. With additional research including clinical trials, STI-571 (now Gleevec®) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic myelogenous leukemia (CML) patients and launched by Novartis in 2001.

The impact of this drug is undeniable. Since its introduction, approximately 28,000 people have been diagnosed with chronic phase CML. Before Gleevec, approximately 6,600 would have died within ﬁ ve years; with Gleevec, that number has been reduced to approximately 980 – that’s 5,620 lives saved and counting. Because the drug is available in pill form and singles out cancer cells, a patient can manage CML while living with high quality of life. Certain other cancer patients can be helped by Gleevec too.

Gleevec is just one drug. Imagine a process that would take the Gleevec example and multiply it. A process that would expand the bottleneck and accelerate the development and clinical testing of promising new discoveries, some with the ability to improve upon current blood cancer statistics. That process is LLS’s Therapy Acceleration Program.

0814172_01_13.indd 4 11/17/08 6:16:21 PM 5 Society Lymphoma & Leukemia The

0814172_01_13-03.indd 5 11/20/08 5:18:00 PM 6

The Therapy Acceleration Program LLS’s Therapy Acceleration Program, launched in ﬁ scal year 2007, addresses some of the hurdles associated with blood cancer drug development, with focused efforts that reduce investment risk and accelerate clinical progress. Combined with LLS’s existing research grant program, funded at $69.1 million in 2008, the Therapy Acceleration Program contributes to an end-to-end solution for the development of new blood cancer therapies.

Biotechnology Accelerator Division Speeds industry discoveries into clinical trials

Laboratory Pre-Clinical Clinical Therapy Discovery Development Trials Approved Acceleration Stage Stage Stage Therapies Program FASTER

Academic Concierge Division Clinical Trials Division Advances LLS grant research Increases clinical trial to clinical applications enrollment

Program ELEMENTS The Therapy Acceleration Program comprises three innovative strategies to hasten progress: the Academic Concierge Division, the Biotechnology Accelerator Division and the Clinical Trials Division.

The Academic Concierge Division identiﬁ es In this stage, generally conducted 1 LLS-funded research projects that have by companies called contract research near-term clinical promise and provides organizations (CROs), scientists study the funding and support needed to advance a treatment’s tissue distribution, stability selected projects to the product stage. and any toxicities associated with its use, as required by the FDA before human As a result of sustained research grant studies can be conducted. The Academic investments, LLS currently has a pipeline Concierge Division acts as a liaison of more than 50 projects with this near-term between researchers and appropriate potential – a portfolio comparable to the CROs. It provides ﬁ nancial support for pipeline of a medium-size pharmaceutical the assembly of large amounts of formal company. The Academic Concierge documentation required by the FDA Division takes advantage of this productive before clinical trials can start. investment in discovery research by assisting selected projects into and through the next stage of product development.

Progress to date: As of the end of ﬁ scal year 2008, the Academic Concierge Division has initiated four pilot projects with three CROs.

0814172_01_13-03.indd 6 11/20/08 11:20:28 PM Through the Biotechnology Accelerator The Biotechnology Accelerator Division 2 Division, LLS allies with companies funds only projects that are close to generating to combine scientifi c and fi nancial data on clinical effi cacy in blood cancer resources and accelerate the development patients. This ensures that the company of promising therapies for blood cancer will be able to gain additional resources 7 patients. Biotechnology companies to complete the testing, registration and are the focus of this program because marketing of new treatments for patients. of their reputation for innovation and Funding projects within companies is a new successful drug development. Historically, direction for LLS; however, other orphan pharmaceutical companies have resisted disease-specifi c organizations have supported developing blood cancer treatments because company research to advance new treatments they are perceived as having less potential for into and through clinical trials. LLS modeled high reward due to relatively small patient the Therapy Acceleration Program with populations. LLS funding will help mitigate

an eye to the best features of those programs. & Lymphoma Society The Leukemia this development barrier.

Progress to date: At the end of ﬁ scal year 2008, the Biotechnology Accelerator Division has contracted with ﬁ ve companies, and more than 20 opportunities are under review.

In the Clinical Trials Division, LLS easy access to them. In addition to travel 3 partners with one or more of the country’s or relocation requirements, barriers include leading clinical trial centers to build the lack of awareness, especially among infrastructure for broader access to blood minorities, and a lack of incentives for local cancer clinical trials and signiﬁ cantly physicians to refer patients to clinical trials. increase enrollment of adult cancer patients. On top of all that, insurance coverage may Planned is a network of Phase I and II not include some or all of the patient-care clinical trial sites that will use new strategies costs associated with a clinical trial. to increase patient enrollment, especially LLS is working through advocacy and among under-represented populations. education to overcome some of the barriers. The percentage of adult cancer patients The Clinical Trials Division focuses participating in clinical trials is just 5 percent, on geographic barriers by taking clinical and only a fraction of trials are for blood trials to patients with one or more cancer therapies. In addition, the median community-based models that will be time to get Phase III trials up and running can deployed in sites across the country. be well over two years. Barriers to enrollment Patients will have access to clinical trials are numerous. Clinical trials are usually in a convenient and familiar setting. staged in major metropolitan or university research centers, so many patients don’t have

Progress to date: In ﬁ scal year 2008, the Clinical Trials Division entered into a novel partnership with Cleveland Clinic Taussig Cancer Institute to create The Clinical Trial Center for Hematologic Malignancies. Six clinical trials, one underway, are planned within three years, with expected enrollment of 100-150 patients.

The Therapy Acceleration Program and LLS’s 2015 VISION The Therapy Acceleration Program is emblematic of a forward-thinking LLS. The need for speed is obvious: lives hang in the balance. In the following pages of the 2008 annual report, you’ll recognize the passion and dedication that have always been hallmarks of this organization. And you should also see signs that LLS is determined to realize its vision with new strategies, renewed energy and an ever-present urgency to ﬁ nd cures.

0814172_01_13-03.indd 7 11/20/08 11:20:29 PM 8 Fiscal Year 2008 Highlights SPEEDING NEW TREATMENTS and CURES…

…Through RESEARCH GRANTS

As of June 2008, LLS was supporting a total of 388 active research projects through grants to academic investigators in the United States, Canada and 14 other countries. These projects were selected for LLS funding by medical and scientiﬁ c experts based on their probability of ﬁ nding new treatments and cures for blood cancers. LLS supported progress in many critical areas this year, including immunotherapies, targeted therapies and new diagnostics. On the following page are a few examples of progress being made by LLS grantees.

0814172_01_13.indd 8 11/17/08 6:16:39 PM Two LLS-funded researchers and their teams are working on a new targeted therapy for lymphoma patients: ● Margaret Shipp, M.D.,* earlier identiﬁ ed a molecule called SYK as essential 9 to the survival of aggressive lymphoma cells. A drug that inhibited SYK killed

most of these cells in the laboratory. Society ● Jonathan Friedberg, M.D.,** showed

good early results of an oral form Margaret Shipp, M.D. Lymphoma of this drug (R788) in a recent clinical & trial. Nearly half of patients showed

improvement. This new, twice-a-day Leukemia

pill may offer a new treatment option The for patients with recurrent small lymphocytic lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Because this treatment is targeted, it is likely to cause fewer side effects than standard treatments.

In the area of new diagnostics, LLS-funded researcher Vivian Oehler, M.D.,*** and her Jonathan Friedberg, M.D. colleagues developed a method to detect, early on, a speciﬁ c, common genetic mutation in chronic myelogenous leukemia (CML) cells. The mutation apparently leads to acquired resistance to targeted drugs used in CML treatments, including Gleevec, Sprycel® and Tasigna®. Because the test can ﬁ nd the mutation far earlier than standard diagnostics, it may give patients who are likely to relapse an opportunity to receive a more effective treatment.

Last year, LLS-funded researcher Carl June, Vivian Oehler, M.D. M.D.,**** and his colleagues developed a new immunotherapy that can rebuild a patient’s immune system within two months of stem cell transplantation, using re-educated immune T-cells. The new treatment has now been tested in post- transplant myeloma patients and in follicular lymphoma patients after standard drug therapy. Combined with new, targeted drugs, these new therapies may soon offer safe and effective alternatives to toxic chemotherapies. Carl June, M.D.

* Dana-Farber Cancer Institute, Boston, MA ** James P. Wilmot Cancer Center, University of Rochester *** Fred Hutchinson Cancer Research Center, Seattle, WA **** University of Pennsylvania, Philadelphia, PA

0814172_01_13-03.indd 9 11/20/08 5:18:16 PM Fiscal Year 2008 Highlights SPEEDING NEW TREATMENTS and CURES…

10 …Through PATIENT SERVICES

LLS information and support offerings for patients, family members and caregivers continued to expand in 2008:

● The Information Resource Center’s ● Our Co-Pay Assistance Program, which master’s-level oncology social workers, began in January 2007, closed out ﬁ scal nurses and health educators responded year 2008 with $4.6 million in ﬁ nancial to 78,524 inquiries from patients, support provided to patients to help families and healthcare professionals. them meet co-pay obligations or health They provided individualized information insurance premiums related to treating on diseases, treatments, clinical trials their blood cancers. and resources available from LLS and other organizations. ● First Connection, which links newly diagnosed patients to trained, ● An audience of 580,000 patients, peer volunteers who have experienced family members and healthcare similar diagnoses, made 7,568 professionals participated in 32 connections this year. Another 12,000 national LLS teleconferences and people participated in LLS Family Webcasts. Another 48,000 attended Support Groups. chapter-based educational programs.

…Through ADVOCACY

This year, LLS’s Ofﬁ ce of Public Policy, in conjunction with our growing Advocates Network of 16,000, was extremely productive at the national and state levels:

● Increased access to U.S. Department ● Launched LLS’s ﬁ rst state-centered of Defense research funding, with advocacy program – focusing on more than $28 million secured to date insurance coverage for patients in clinical trials. This year, Ohio, Wyoming and ● Defeated efforts to restrict payments the District of Columbia have passed new for radioimmunotherapy treatments laws providing coverage – with the state for lymphoma patients total now up to 24. ● Successfully passed the Caroline Pryce Walker Conquer Childhood Cancer Act – providing a focus and funding on childhood cancer at the National Cancer Institute

0814172_01_13-03.indd 10 11/20/08 5:18:17 PM 11 Society Lymphoma & Leukemia The

0814172_01_13-03.indd 11 11/20/08 5:18:25 PM Fiscal Year 2008 Highlights SPEEDING NEW TREATMENTS and CURES…

12 …Through FUNDRAISING CAMPAIGNS

All of our major fundraising campaigns continued their strong contributions to advancing LLS’s mission.

Team In Training® (TNT) recruited Light The Night® Walk broke its own for a new, co-branded event this year – record in fi scal year 2008, raising nearly The Nation’s TriathlonTM, to benefi t The $40 million. Twenty-one new national/ Leukemia & Lymphoma Society, which regional partners were recruited this was held in Washington, DC in September. year, representing a combined $1.6 million The event enjoyed early sell-out; TNT in revenue to help advance LLS’s mission. held the envious position as “the only School & YouthSM Programs now boast way to enter.” The Nation’s Triathlon joins participation among 21 percent of the the Nike Women’s Marathon, A Race nation’s schools. The programs fi nished to Benefi t The Leukemia & Lymphoma off the 2007/2008 school year with 23,000 Society, as LLS’s second co-branded event, registered schools and raised more than a strategy that is helping us build the LLS $19 million, demonstrating that kids can brand in association with the valuable really make a difference. asset that is Team In Training.

…Through DONOR DEVELOPMENT

Generous contributions from individual Thanks to far-sighted individuals who benefactors, foundations and corporations remembered LLS in their estate plans, generated $23.5 million, a 14 percent signifi cant bequest income was received. increase over the prior year. These funds Many friends responded to invitations support cutting-edge researchers at to participate in our Charitable Gift renowned institutions nationally and Annuity Program, ensuring our ability abroad, a wide array of community-based to support research and patient services patient services and therapy acceleration in the years ahead. initiatives that will bring more therapies For the fi rst time, $10,000+ donors were able to more patients faster. to invest in a portfolio of research projects organized around a specifi c blood cancer interest. Like mutual funds, the portfolios minimize risk and maximize opportunity.

0814172_01_13-03.indd 12 11/20/08 5:18:27 PM 13 Society Lymphoma & Leukemia The

0814172_01_13.indd 13 11/17/08 6:17:03 PM Research GRANTS

Specialized Center of Research Beverly S. Mitchell, MD * Daniel Billadeau, PhD The Specialized Center of Research Stanford University Mayo Clinic and Foundation program encourages multidisciplinary research by teams of leading-edge Stephen Nimer, MD 7 Marie Bleakley, MD * academic investigators that hastens Memorial Sloan-Kettering Fred Hutchinson Cancer the discovery and development of better Cancer Center Research Center treatments for leukemia, lymphoma 14 8 and myeloma patients. A center Michael Thirman, MD Marzenna Blonska, PhD 1 Dr. John Bushweller is funded in part is composed of at least three independent The University of Chicago The University of Texas by the Martinsville Area Community Foundation. research programs that are integrated M.D. Anderson Cancer Center Cheryl L.Willman, MD and supported by scientifi c core 2 Dr. Riccardo Dalla-Favera is funded Catherine Bollard, MD laboratories. University of New Mexico in part by Jonathan Plutzik & Lesley Baylor College of Medicine Goldwasser Family Foundation, Joseph Jerry Adams, PhD S. and Diane H. Steinberg, The Edward Career Development Program Tatiana Bondar, PhD 11 Milstein Foundation, James and The Walter and Eliza Hall Yale University Karen Finkel, Paul and Susan Friedman, Institute of Medical Research The Career Development Program provides stipends to investigators The J.T. Tai Foundation, Tom Marano, Ivan Borrello, MD Jeffrey and Katina Mayer, Michael Frederick Alt, PhD of exceptional promise in the early The Johns Hopkins University and Elin Nierenberg and Family, CBR Institute for Biomedical stages of their careers, helping them Daniel and Carol Spina, Jonathan devote their careers to leukemia, and Jeannie Lavine and Family, Research, Inc. Randy Brutkiewicz, PhD lymphoma and/or myeloma research. Deborah and Jeff Briggs, Tracy and Indiana University School of Medicine Jon Aster, MD, PhD Frank Collins, and James F. Egan. Peter Adams, PhD Brigham and Women’s Hospital Gerd Bungartz, PhD 3 Dr. Anthony Green is funded in part Fox Chase Cancer Center University of Pennsylvania by Mark Rosen. Irwin Bernstein, MD Fred Hutchinson Cancer Ioannis Aifantis, PhD * 4 Dr. James Griffi n is funded in part by Laura Buttitta, PhD * Research Center New York University the F.M. Kirby Foundation, Susan and Fred Hutchinson Cancer Rick Theder – Cure Kids Cancer Golf Research Center and Karyn Research Fund. John H. Bushweller, PhD 1 David Allman, PhD University of Virginia University of Pennsylvania 5 Kenneth Campellone, PhD * Dr. Ronald Levy is funded in part by John Andrews, Greg and Michelle Becker, University of California, Berkeley John Byrd, MD Shannon Anderson, PhD * Alan Brayton, East Bay Community The Ohio State University University of California, San Francisco Foundation, Charles Gibbs, Jr., Lesley Julie Canman, PhD Mansford, Jeff and Kristi Miller, Guy and Ludwig Institute for Cancer Research Linda Nohra, Jerry and Lois Rosenblum, Riccardo Dalla-Favera, MD * 2 Jennifer Antonchuk, PhD The San Francisco Foundation, Lee and University of Edinburgh Columbia University Kate Carroll, PhD Laurie Schneider, Silicon Valley Community University of Michigan Foundation, Vineman, Inc., The Tom Woods Brian Druker, MD Toshiyuki Araki, PhD Memorial Fund, Lunardi’s Supermarket, Howard Hughes Medical Institute University of Toronto Martin Carroll, MD Inc., The Wayne and Gladys Valley Oregon Health & Science University Foundation, The Joseph C. Sanfi lippo University of Pennsylvania Cancer Institute Philippe Armand, MD, PhD Memorial Fund and anonymous Dana-Farber Cancer Institute donors (2). Andrew Carter, PhD Carolyn Felix, MD 6 Dr. Scott Lowe is funded in part by the * University of California, San Francisco The Children’s Hospital Laura Attardi, PhD Altschul Foundation/Reichman Memorial. Stanford University of Philadelphia * Pedro Carvalho, PhD 7 Dr. Stephen Nimer is funded in part by Harvard Medical School Anthony Green, MD, PhD 3 Claire Attwooll, PhD 9 The John and Shirley Davies Foundation. Memorial Sloan-Kettering University of Cambridge Lucio Castilla, PhD 8 Dr. Michael Thirman’s grant is funded Cancer Center University of Massachusetts in part by The Coleman Foundation, James Griffi n, MD 4 Medical School The Pamela B. Katten Memorial Dana-Farber Cancer Institute Christopher Bakal, PhD Leukemia Research Foundation, Harvard Medical School Dr. Ralph and Marian Falk Medical Asher Chanan-Khan, MD * 12 Helen Heslop, MD * Research Trust, Alverin M. Cornell Roswell Park Cancer Institute Baylor College of Medicine Bryan Barnhart, PhD Foundation, Paul & Joan Rubschlager University of Pennsylvania Foundation, Rochelle Simms, Helen Brach Yang Chao, PhD Foundation, Donald Porteous, William Carl June, MD Sefton, Daniel and Ada Rice Foundation, Elly Barry, MD Princeton University University of Pennsylvania Berner Charitable and Scholarship Dana-Farber Cancer Institute Danica Chen, PhD Foundation, Alberto-Culver Company, Thomas Kipps, MD, PhD Massachusetts Institute of Technology Bonnie Valiant, TAP Pharmaceuticals, University of California, San Diego Michael Bassik, PhD Bruce Allen and HealthInfo. University of California, San Francisco Jihua Chen, MD, PhD 9 Larry Kwak, MD, PhD Dr. Claire Attwooll is fully funded by Dana-Farber Cancer Institute the Hildegarde D. Becher Foundation, Inc. The University of Texas Uttiya Basu, PhD * M.D. Anderson Cancer Center CBR Institute for Biomedical 10 Wei-Yi Chen, PhD * Dr. Linda Baughn is funded in part by Research, Inc. The St. Valentine’s Day Luncheon and Rockefeller University Ronald Levy, MD 5 Style Show in honor of Lynda Adleta. Stanford University Linda Baughn, PhD 10 Yi-Bin Chen, MD * 11 Dr. Tatiana Bondar is fully funded by Albert Einstein College of Medicine Massachusetts General Hospital the Gertrude B. Elion Research Fund. Jonathan Licht, MD Northwestern University Michael Begley, PhD 12 Dr. Asher Chanan-Khan is funded in part Tao Cheng, MD * Beth Israel Deaconess Medical Center by Lisa and Brian Bee – Spin 4 the Cure. University of Pittsburgh Scott Lowe, PhD * 6 Cold Spring Harbor Laboratory Avinash Bhandoola, MD, PhD Vivian Choi, PhD * University of Pennsylvania * Newly awarded or renewed grants CBR Institute for Biomedical Tak Mak, PhD, DSc in fi scal year 2009. Research, Inc. University of Toronto Anja-Katrin Bielinsky, PhD * University of Minnesota, Twin Cities Stella Chou, MD Susan Biggins, PhD The Children’s Hospital of Philadelphia Fred Hutchinson Cancer Research Center

0814172_14_36-02.indd 14 11/20/08 5:26:05 PM 0814172_14_36-02.indd 15 of Medicine New York UniversitySchool Ludovic Deriano, PhD Wistar Institute Zhong Deng, PhD Cancer Institute Oregon Health & Science University Michael Deininger, MD, PhD University ofOxford Renee dePooter, PhD Research Center Fred HutchinsonCancer Michael Davis, PhD Dana-Farber CancerInstitute Jeffrey Davies, MD, PhD Research, Inc. CBR Institute for Biomedical Abhishek Datta, PhD New York University Vincenzo D’Angiolella, PhD at ChapelHill University ofNorthCarolina Blossom Damania, PhD Research Center Fred HutchinsonCancer Mari Dallas, MD University ofCalifornia,SanFrancisco Monique Dail, PhD University ofCalifornia,SanDiego Warren D’Souza, PhD University ofCalifornia,SanDiego Louise D’Cruz, PhD The UniversityofChicago John Crispino, PhD Stanford University Alexandre Costa, PhD Case Western ReserveUniversity Kenneth Cooke, MD Yale University Pasquale Cirone, PhD Novartis Forschungsstiftung Rafal Ciosk, PhD New York University Maria Ciofani, PhD Stanford University Karlene Cimprich, PhD University ofPennsylvania Elaine Chung, PhD University ofMichigan Sergei Chuikov, PhD Brown University Wen-Ming Chu, MD, PhD Research Center Fred HutchinsonCancer Eric Chow, MD * * * * 13 * * Tracy Diamond, PhD Massachusetts GeneralHospital Luisa DiStefano, PhD University ofCalifornia,Berkeley Abby Dernburg, PhD Pinghui Feng, PhD Baylor CollegeofMedicine Xin-Hua Feng, PhD Massachusetts InstituteofTechnology David Feldser, PhD Rockefeller University Niklas Feldhahn, PhD University ofMinnesota,Twin Cities Michael Farrar, PhD Stanford University Alice Fan, MD University ofToronto University HealthNetwork, Kolja Eppert, PhD University ofCalifornia,Berkeley Nicholas Endres, PhD Massachusetts InstituteofTechnology Elkin,Sheryl PhD Vanderbilt UniversityMedicalCenter Christine Eischen, PhD of Medicine New York University School Takeshi Egawa, MD, PhD The UniversityofChicago Wei Du, PhD Harvard University Jinyan Du, PhD The UniversityofChicago Gregory Driessens, PhD M.D. AndersonCancerCenter The University of Texas Chen Dong, PhD University ofPennsylvania J. Alan Diehl, PhD University ofPennsylvania The JohnsHopkinsUniversity Ephraim Fuchs, MD University ofRochester Jonathan Friedberg, MD University ofPennsylvania Noelle Frey, MD University ofVirginia Daniel Foltz, PhD Scripps Research Institute Josephine Ferreon, PhD Columbia University Adolfo Ferrando, MD, PhD Dana-Farber CancerInstitute Hui Feng, PhD Medical CenteratDallas The University of Texas, Southwestern 14 * 15 16 * * * * * Medical Center Cincinnati Children’s Hospital H. LeightonGrimes, PhD Research, Inc. CBR Institute for Biomedical Monica Gostissa, PhD Brigham andWomen’s Hospital Wendy Gordon, PhD Mount SinaiSchoolofMedicine Florent Ginhoux, PhD University ofArizona Sourav Ghosh, PhD Brigham andWomen’s Hospital Benjamin Gewurz, MD, PhD Bucknell University Julie Gates, PhD Medical Research Burnham Institutefor Jason Garrison, PhD Dana-Farber CancerInstitute Neil Ganem, PhD Dana-Farber CancerInstitute Boyi Gan, PhD of Technology Massachusetts Institute Kyriaki Galani, PhD University ofCalifornia,SanFrancisco David Hesslein, PhD Research Center Fred HutchinsonCancer Kiersten Henderson, PhD University ofCalifornia,LosAngeles Ian Henderson, PhD Children’s HospitalBoston Xi He, PhD at ChapelHill University ofNorthCarolina Jin He, MD, PhD Peter MacCallumCancerInstitute Kieran Harvey, PhD Princeton University Danna Hargett, PhD Ludwig InstituteforCancerResearch Joo SeokHan, PhD Research Center Fred HutchinsonCancer Tomoko Hamma, PhD Massachusetts InstituteofTechnology Allan Gurtan, PhD University ofCalifornia,LosAngeles Beichu Guo, PhD Biomedical Research Whitehead Institutefor David Guertin, PhD Columbia University Alla Grishok, PhD * 17 * * * * 17 16 15 14 13 * Newly awarded orrenewed grants Dr. BeichuGuoisfullyfundedby Dr. by PinghuiFengisfundedinpart in ﬁ scal year 2009. Research Fellow. D.the Mary Averbrook Memorial and StyleShow. The St. Valentine’s DayLuncheon Foundation. Birnbaum Scholar, isfullyfundedby The Stephen Dr. Kolja Eppert, a Stephen Birnbaum Family Fund. Irving Dr. Jinyan Du is fully funded by the by Steve andLisaBoom. Dr. JeffreyDaviesisfundedinpart 11/20/08 5:26:06 PM

The Leukemia & Lymphoma Society 15 Research GRANTS (CONTINUED)

Elizabeth Hexner, MD * Sumin Kang, PhD * Francene Lemoine, PhD University of Pennsylvania Emory University Duke University Medical Center

Gilles Hickson, PhD Cheng-Fu Kao, PhD Gustavo Leone, PhD 21 University of California, San Francisco Academia Sinica The Ohio State University

* * Anthony Letai, MD, PhD * 16 Angela Hilliker, PhD Tarun Kapoor, PhD University of Arizona Rockefeller University Dana-Farber Cancer Institute 18 Dr. Jonathan Irish is funded in part by Rob and Shikha Chandra and Amy Holdorf, PhD David Kashatus, PhD Anthony Leung, PhD Aaron Konstam. Mount Sinai School of Medicine Duke University Medical Center Massachusetts Institute of Technology 19 Dr. Karen Keeshan, a Stephen Birnbaum Scholar, is fully funded by The Stephen * Eun-Jin Hong, PhD Samuel Katz, MD, PhD * Mark Levis, MD, PhD Birnbaum Foundation. Harvard Medical School Dana-Farber Cancer Institute The Johns Hopkins University 20 Dr. Michelle Kelliher is funded in part Heedeok Hong, PhD * Barbara Kee, PhD * Zachary Lewis, PhD * by the Remillard Family Foundation. University of Oregon University of California, Los Angeles The University of Chicago 21 Dr. Gustavo Leone is funded in part by the Doug Steele Golf Fore Life Daniel Hostetter, PhD Younghoon Kee, PhD * Shaoguang Li, MD, PhD 22 Tournament. University of California, San Francisco Dana-Farber Cancer Institute The Jackson Laboratory 22 Dr. Shaoguang Li is funded in part Ke Hu, PhD Scott Keeney, PhD Willis Li, PhD by Mark and Christine Kraemer and Charles and Lynda Kraemer. Indiana University School of Medicine Memorial Sloan-Kettering University of Rochester Cancer Center Jian Hu, PhD * Zihai Li, MD, PhD Dana-Farber Cancer Institute Karen Keeshan, PhD 19 University of Connecticut University College Cork Jing Huang, PhD Chengyu Liang, MD, PhD Wistar Institute Michelle Kelliher, PhD 20 University of Southern California University of Massachusetts Jian Huang, MD, PhD Medical School Xiaozhen Liang, PhD University of Pennsylvania Emory University Kitai Kim, PhD Tara Huber, PhD Children’s Hospital Boston Sergiy Libert, PhD * Genome Institute of Singapore Massachusetts Institute of Technology TaeSoo Kim, PhD * Matthias Hundt, MD Harvard Medical School Xin Lin, PhD La Jolla Institute for Allergy The University of Texas & Immunology Scott Kogan, MD M.D. Anderson Cancer Center University of California, San Francisco Kristen Hurov-Neely, PhD Weei-Chin Lin, MD, PhD Brigham and Women’s Hospital Minoree Kohwi, PhD * University of Alabama at Birmingham University of Oregon Jonathan Irish, PhD 18 Jidong Liu, PhD Stanford University Motonari Kondo, MD, PhD Memorial Sloan-Kettering Duke University Medical Center Cancer Center Madhulika Jain, PhD * Harvard Medical School Mei Kong, PhD Ling Liu, PhD University of Pennsylvania Stanford University Robert Jenq, MD Memorial Sloan-Kettering Valery Krizhanovsky, PhD Miao-Chia Lo, PhD Cancer Center Cold Spring Harbor Laboratory University of California, San Diego

Peng Ji, PhD * Matthew Krummel, PhD Mignon Loh, MD Whitehead Institute for University of California, San Francisco University of California, San Francisco Biomedical Research Marc Kvansakul, PhD Simonne Longerich, PhD Jin Jiang, PhD The Walter and Eliza Hall Yale University The University of Texas, Southwestern Institute of Medical Research Medical Center at Dallas Michelle Longworth, PhD Samy Lamouille, PhD Massachusetts General Hospital Hao Jiang, PhD University of California, San Francisco Rockefeller University Li-Fan Lu, PhD Ke Lan, MD, PhD University of Washington Kristen Johnson, PhD University of Pennsylvania New York University Edward Luk, PhD Mark Lanasa, MD, PhD National Institutes of Health Craig Jordan, PhD Duke University Medical Center University of Rochester Matthias Lutolf, PhD Emma Langley, PhD Stanford University Emma Josefsson, PhD * Scripps Research Institute The Walter and Eliza Hall Yunmei Ma, PhD Institute of Medical Research Nicolas Larmonier, PhD The Johns Hopkins University University of Arizona * Newly awarded or renewed grants Przemyslaw Juszczynski, MD, PhD Xiaoju Ma, PhD in ﬁ scal year 2009. Dana-Farber Cancer Institute Nicholas Larsen, PhD Harvard Medical School Harvard Medical School Axel Kallies, PhD Hiten Madhani, MD, PhD The Walter and Eliza Hall Institute Sang Eun Lee, PhD University of California, San Francisco of Medical Research The University of Texas Health Science Center at San Antonio

0814172_14_36-02.indd 16 11/20/08 5:26:06 PM 0814172_14_36-02.indd 17 The UniversityofTexas atAustin Tanya Paull, PhD Massachusetts GeneralHospital Dongsu Park, PhD Medical Center Cincinnati Children’s Hospital Qishen Pang, PhD Cancer Center Memorial Sloan-Kettering Jing Pan, PhD The JohnsHopkinsUniversity Duojia Pan, PhD M.D. AndersonCancerCenter The University of Texas Orlowski,Robert MD, PhD (German CancerResearch Center) Deutsches Krebsforschungszentrum Christopher Oakes, PhD University ofOregon Sean O’Rourke, PhD Duke UniversityMedicalCenter Leta Nutt, PhD University ofCalifornia,SanFrancisco Geeta Narlikar, PhD Yale University Anita Nag, PhD Sciences Research Center Alexander Fleming Biomedical George Mosialos, PhD The JohnsHopkinsUniversity Tammy Morrish, PhD Rutgers University Alexandre Morozov, PhD McGill University Nam-Sung Moon, PhD Harvard MedicalSchool Danesh Moazed, PhD University ofVirginia Stavroula Mili, PhD Brigham andWomen’s Hospital Thomas Mercher, PhD School ofMedicine The Johns Hopkins University Joshua Mendell, MD, PhD of CornellUniversity Weill MedicalCollege Ari Melnick, MD Drexel University Alexander Mazin, PhD University ofCalifornia,SanFrancisco Carla Martins, PhD Peter MacCallumCancerCentre Vanessa Marsden, PhD at ChapelHill University ofNorthCarolina Aron Marquitz, PhD * * * * * * * * John Perry, PhD The OhioStateUniversity Danilo Perrotti, MD, PhD University ofPennsylvania Alexander Perl, MD Stanford University Lauren Richie-Ehrlich, PhD Duke UniversityMedicalCenter Tannishtha Reya, PhD University ofCalifornia,Berkeley Andrey Revyakin, PhD The JohnsHopkinsUniversity Linda Resar, MD Austrian AcademyofSciences Center for Molecular Medicine, Lily RemsingRix, PhD Eotvos LorandUniversity Attila Remenyi, PhD National CancerInstitute Anand Ranjan, PhD Massachusetts InstituteofTechnology John Randell, PhD at ChapelHill University ofNorthCarolina Dale Ramsden, PhD Scripps Research Institute Rajesh Ramachandran, PhD Biomedical Research Whitehead Institutefor Priyamvada Rai, PhD Research Center Fred HutchinsonCancer Gunnar Ragnarsson, MD Northwestern University Ishwar Radhakrishnan, PhD Chinese AcademyofSciences Youcun Qian, PhD University ofWashington Bin Qian, PhD University ofCalifornia,SanFrancisco Miles Pufall, PhD Scripps Research Institute Thomas Pucadyil, PhD University ofKansasMedicalCenter Philippe Prochasson, PhD University ofWashington Prlic,Martin PhD University ofIllinois Supriya Prasanth, PhD Rockefeller University Lisa Postow, PhD Hospitals, Inc. New EnglandMedicalCenter Christos Polytarchou, PhD University ofCalifornia,SanFrancisco Hyewon Phee, PhD Stowers InstituteforMedicalResearch * 25 * 23 * 24 * * Stefanie Sarantopoulos, MD, PhD Harvard MedicalSchool Adrian Salic, PhD Stanford University Karen Sachs, PhD University ofToronto Laurent Sabbagh, PhD New York University Hyung Ryoo, PhD Università diPerugia Loredana Ruggeri, MD, PhD Brigham andWomen’s Hospital Monideepa Roy, PhD University ofMichigan Theodora Ross, MD, PhD at ChapelHill University ofNorthCarolina Edward Rogers, PhD Rockefeller University Davide Robbiani, MD, PhD Duke UniversityMedicalCenter David Rizzieri, MD Mayo ClinicRochester Robin Ricke, PhD Dana-Farber CancerInstitute Peter Sicinski, MD, PhD University ofWisconsin at Madison Erika Shor, PhD Yale University Warren Shlomchik, MD University ofCalifornia,SanDiego Wei-Jong Shia, PhD Albert EinsteinCollegeofMedicine David Sharp, PhD Research, Inc. CBR Institute for Biomedical Sonia Sharma, PhD Cold SpringHarborLaboratory Camile Semighini, PhD Cancer Institute Oregon Health & Science University Rosalie Sears, PhD Beth IsraelDeaconessMedicalCenter Ralph Scully, MD, PhD University ofCalifornia,LosAngeles Suzanne Schubbert, PhD & Immunology La JollaInstituteforAllergy Stephen Schoenberger, PhD University ofToronto University HealthNetwork, Aaron Schimmer, MD, PhD University ofToronto Bernie Sattin, PhD Dana-Farber CancerInstitute 28 * * * 26 * * 27 * 28 27 26 25 24 23 * Newly awarded orrenewed grants Dr. Erika Shor is funded in part by Dr. Warren Shlomchik is fully funded Dr. Wei-Jong Shia, aStephenBirnbaum Dr. Linda Resar is funded in part by Dr. Danilo Perrotti is funded in part Dr. Alexander Perl is funded in part by in ﬁ scal year 2009. Elsa SchoeneichMedicalResearchFund. the Greater Milwaukee Foundation’s by The Newman Family. Foundation. Birnbaum Scholar, isfullyfundedby The Stephen the Cora andJohnH. DavisFoundation. andLyndaKraemer.and Charles by Mark and Christine Kraemer the DouglasKrollResearchFoundation. 11/20/08 5:26:07 PM

The Leukemia & Lymphoma Society 17 Research GRANTS (CONTINUED)

Rachael Siegel, PhD 29 Katharine Ullman, PhD Zhaohui Wu, MD, PhD Columbia University University of Utah University of Wisconsin at Madison

Jonathan Snow, PhD Craig Vander Kooi, PhD 32 Geng Wu, PhD Children’s Hospital Boston University of Kentucky Children’s Hospital Boston

Yongcheng Song, PhD Lidia Vasilieva, PhD Ning Wu, PhD 18 University of Illinois Harvard Medical School Beth Israel Deaconess Medical Center 29 Dr. Rachael Siegel is partly funded by Lisa and Brian Bee – Spin 4 the Cure. Zhou Songyang, PhD Shobha Vasudevan, PhD * Tao Wu, PhD 30 Baylor College of Medicine Yale University Harvard Medical School Dr. Michael Teitell is fully funded by the Mary D. Averbrook Memorial Research Fellow. Erinn Soucie, PhD Ramiro Verdun, PhD Huafeng Xie, PhD * Center National de la Recherche Salk Institute for Biological Studies Dana-Farber Cancer Institute 31 Dr. Jennifer Trowbridge is funded in part Scientiﬁ que by the John W. Alden Trust. Jose Villadangos, PhD Ming Xu, PhD 36 32 Dr. Craig Vander Kooi is funded in part Tracy Staton, PhD * The Walter and Eliza Hall Institute The University of Texas, by Jeffrey’s Journey. Harvard School of Public Health of Medical Research Southwestern Medical Center at Dallas 33 Dr. Roland Walter is funded in part by Milan Stojanovic, PhD Dan Vogl, MD Jianchang Yang, MD, PhD * the Dan Gleason Memorial Research Columbia University University of Pennsylvania Nevada Cancer Institute Fund. 34 Dr. Hans-Guido Wendel is funded in part Travis Stracker, PhD Carl Walkley, PhD Xiaolu Yang, PhD by the New York State Department Memorial Sloan-Kettering St. Vincent’s Institute University of Pennsylvania of Health, in honor of Senator Cancer Center of Medical Research Carl L. Marcellino. Tso-Pang Yao, PhD 35 Matthew Strout, MD, PhD Johannes Walter, PhD Duke University Medical Center Dr. Joseph Wiemels is fully funded by Team Friends of Heroes, Honoring Yale University Harvard Medical School Pediatric Heroes. Tingting Yao, PhD Wojciech Swat, PhD * Roland Walter, MD, PhD 33 Stowers Institute for Medical Research 36 Dr. Ming Xu is funded in part by Washington University Fred Hutchinson Cancer The St. Valentine’s Day Luncheon School of Medicine Research Center Defne Yarar, PhD and Style Show. Whitehead Institute Gergely Szakacs, MD, PhD Demin Wang, PhD for Biomedical Research Biological Research Center, Blood Research Institute, Hungarian Academy of Sciences Blood Center of Southeastern Taofei Yin, PhD Wisconsin University of North Carolina Jason Tanny, PhD at Chapel Hill University of Montreal Dong Wang, PhD Stanford University Tong Yin, PhD * Vera Tarakanova, PhD Stowers Institute for Medical Research Washington University Jing Wang, MD, PhD School of Medicine CBR Institute for Biomedical Carol Ying, PhD * Research, Inc. Columbia University Ewan Taylor, PhD Scripps Research Institute Donghai Wang, PhD Tomoki Yokochi, PhD CBR Institute for Biomedical Florida State University Michael Teitell, MD, PhD 30 Research, Inc. University of California, Los Angeles Akihiko Yokoyama, PhD Gang (Greg) Wang, PhD * Stanford University Matthew Thomas, PhD Rockefeller University University of Pennsylvania Hongtao Yu, PhD Wenyi Wei, PhD The University of Texas, Southwestern David Toczyski, PhD Beth Israel Deaconess Medical Center Medical Center at Dallas University of California, San Francisco Mitchell Weiss, MD, PhD Hoi-Ying (Elsie) Yu, PhD * Giovanni Tonon, MD, PhD The Children’s Hospital Brandeis University Dana-Farber Cancer Institute of Philadelphia Jianbo Yue, PhD Ivan Topisirovic, MD, PhD Markus Welcker, MD University of Hong Kong IRIC – Institut de Recherche en Fred Hutchinson Cancer Immunovirologie et en Cancerologie Research Center Shan Zha, MD, PhD Children’s Hospital Boston Emily Troemel, PhD Hans-Guido Wendel, MD 34 Massachusetts General Hospital Memorial Sloan-Kettering Tong Zhang, PhD Cancer Center Dartmouth College Jennifer Trowbridge, PhD 31 Dana-Farber Cancer Institute Gerlinde Wernig, MD Yanping Zhang, PhD Brigham and Women’s Hospital University of North Carolina Hsin-Yue Tsai, PhD * at Chapel Hill University of Massachusetts Joseph Wiemels, PhD 35 Medical School University of California, San Francisco Weiguo Zhang, PhD Duke University Medical Center Vasiliki Tsakraklides, PhD William Wierda, MD, PhD * Newly awarded or renewed grants Massachusetts Institute of Technology The University of Texas Zhengjian Zhang, PhD in ﬁ scal year 2009. M.D. Anderson Cancer Center University of California, Berkeley Jessica Tyler, PhD University of Colorado Health Sarah Wignall, PhD Baochun Zhang, MD, PhD * Sciences Center Stanford University CBR Institute for Biomedical Research, Inc. Jasmine Wong, PhD University of California, San Francisco

0814172_14_36-02.indd 18 11/20/08 5:26:07 PM 0814172_14_36-02.indd 19 Roswell ParkCancerInstitute Asher Chanan-Khan, MD University ofUtah Nicola Camp, PhD The OhioStateUniversity Michael Caligiuri, MD The OhioStateUniversity John Byrd, MD Lund University Carl Borrebaeck, DSc University ofMontreal Katherine Borden, PhD University ofMinnesota,Twin Cities Bruce Blazar, MD Stanford University Helen Blau, PhD City ofHopeNationalMedicalCenter Smita Bhatia, MD University ofRochester Steven Bernstein, MD University ofSydney Linda Bendall, PhD Research Center Fred HutchinsonCancer Antonio Bedalov, MD, PhD University ofWashington Pamela Becker, MD, PhD University ofMiami Julio Barredo, MD at ChapelHill University ofNorthCarolina Baldwin,Albert PhD University ofMaryland Maria Baer, MD Mayo ClinicandFoundation Stephen Ansell, MD, PhD patients’ lives. ultimately prolongingandenhancing into new, safe andeffective treatments, to translate basicbiomedicaldiscoveries mostlikely deemed byadvisors ourexpert outstandinginvestigations supports The Translational ResearchProgram Translational ResearchProgram Harvard SchoolofPublicHealth Weiguo Zou, PhD University ofCalifornia,Berkeley Daniel Zilberman, PhD Research, Inc. CBR Institute for Biomedical Yubin Zhou, PhD Harvard MedicalSchool Rui Zhou, PhD of CornellUniversity Weill MedicalCollege Pengbo Zhou, PhD * * * * 37

* 38 *

39 * Selina Chen-Kiang, PhD University ofMinnesota,Twin Cities Wei Chen, MD, PhD University ofPittsburgh Preet Chaudhary, MD, PhD Medical UniversityofSouthCarolina Daniel Fernandes, PhD, DSc Stanford University Dean Felsher, MD, PhD Northwestern University Elizabeth Eklund, MD Engineering andBiotechnology International Centre for Genetic Dimitar Efremov, MD, PhD University ofCambridge Ming-Qing Du, MD, PhD Baylor CollegeofMedicine Gianpietro Dotti, MD at ChapelHill University ofNorthCarolina Dirk Dittmer, PhD Case Western ReserveUniversity Clark Distelhorst, MD of CornellUniversity Weill MedicalCollege Maurizio DiLiberto, PhD Stanford University Joseph DiCarlo, MD Boston University Gerald Denis, PhD University ofColoradoatDenver James DeGregori, PhD The JohnsHopkinsUniversity Chi Dang, MD, PhD Brigham andWomen’s Hospital George Daley, MD, PhD Dana-Farber CancerInstitute Alan D’Andrea, MD University ofSouthernCalifornia Wendy Cozen, DO, MPH University ofFlorida Christopher Cogle, MD Stanford University Michael Cleary, MD Brigham andWomen’s Hospital Rachael Clark, MD, PhD Cancer Center Johns HopkinsComprehensive I.Curt Civin, MD Rush UniversityMedicalCenter Kent Christopherson, PhD University ofLouisville Jason Chesney, MD, PhD of CornellUniversity Weill MedicalCollege * 41 * * * 40 * University ofPennsylvania Alan M. Gewirtz, MD Medical School UMDNJ –RobertWood Johnson Celine Gelinas, PhD M.D. AndersonCancerCenter The University of Texas Guillermo Garcia-Manero, MD M.D. AndersonCancerCenter The University of Texas Varsha Gandhi, PhD Hospital andClinic Scott andWhiteMemorial Frankel,Arthur MD M.D. AndersonCancerCenter The University of Texas Richard Ford, MD, PhD Emory University Christopher Flowers, MD, MS University ofMichigan James Ferrara, MD Columbia University Adolfo Ferrando, MD, PhD Mayo ClinicRochester Fernandez-Zapico,Martin MD Dana-Farber CancerInstitute Donald Kufe, MD M.D. AndersonCancerCenter The University of Texas Marina Konopleva, MD, PhD M.D. AndersonCancerCenter The University of Texas Krishna Komanduri, MD Stanford University Susan Knox, MD, PhD Cancer Center Memorial Sloan-Kettering Tomas Kirchhoff, PhD Mayo ClinicandFoundation Scott Kaufmann, MD, PhD University ofRochester Craig Jordan, PhD University ofArizona Laurence Hurley, PhD, DSc & Research Institute H. Lee Mofﬁtt Cancer Center Lori Hazlehurst, PhD University ofVirginia Jolanta Grembecka, PhD The JohnsHopkinsUniversity Steven Gore, MD Karp FamilyResearch Laboratories Harvard StemCellInstitute, Dana-Farber/Harvard CancerCenter, Howard HughesMedicalInstitute, Harvard MedicalSchool, D. Gilliland, Gary MD, PhD Dana-Farber CancerInstitute Irene Ghobrial, MD * * * 47 46 * 42 43 45 * * * 48 * * 44 * 47 46 45 44 43 42 41 40 39 38 37 * 48 Newly awarded orrenewed grants Dr. by Craig Jordanisfundedinpart Dr. isfullyfundedby IreneGhobrial Dr. by isfundedinpart Alan Gewirtz Dr. Garcia-Manero isfunded Guillermo Dr. Varsha Gandhi is fully funded by Dr. Arthur Frankel is funded in part by Dr. Jason Chesney is funded in part by Dr. Carl Borrebaeck is fully funded by Dr. Blazarisfullyfundedby gifts Bruce Dr. Smita Bhatia is fully funded by Dr. isfundedinpart Komanduri Krishna Dr. Joseph DiCarlo is funded in part by in ﬁ scal year 2009. the ForJulieFoundation, Inc. Kroll ResearchFoundation. Robert and JoAnna Behl and the Douglas Cox. BMC ofLarry West inmemory Bee–Spin4theCure. Lisa andBrian of Mary Anne McClurkin-Wolfe. in part by John R. Jones, III, in memory the JimJacobsLeukemia ResearchFund. and StyleShow. The St. Valentine’s DayLuncheon The MansbachFoundation, Inc. an anonymousdonor. ofRogerMadoff. made inmemory the PeterResearchFund. Memorial Burg by theMeredithCowden Foundation. 11/20/08 5:26:08 PM

The Leukemia & Lymphoma Society 19 Research GRANTS (CONTINUED)

Larry Kwak, MD, PhD Jonathan Pollack, MD, PhD James Wooldridge, MD The University of Texas Stanford University University of Iowa M.D. Anderson Cancer Center Miles Prince, MD Catherine Wu, MD Wen-Hwa Lee, PhD Peter MacCallum Cancer Centre Dana-Farber Cancer Institute University of California, Irvine Feyruz Rassool, PhD Mingjiang Xu, MD, PhD 20 Hsiou-Chi Liou, PhD University of Maryland Mount Sinai School of Medicine 49 Dr. Jeffrey Molldrem is funded in part Weill Medical College by the Meredith Cowden Foundation. of Cornell University Yosef Refaeli, PhD 52 B. Hilda Ye, PhD 50 National Jewish Medical Albert Einstein College of Medicine Dr. Sherie Morrison is fully funded by the Mary D. Averbrook Memorial Mignon Loh, MD * Research Center Research Fellow. University of California, San Francisco Tim Yen, PhD Susan Rheingold, MD * Fox Chase Cancer Center 51 Dr. Robert Orlowski is funded in part Sagar Lonial, MD The Children’s Hospital of Philadelphia by The Mansbach Foundation, Inc. Emory University Qing Yi, MD, PhD * 52 Dr. Yosef Refaeli is funded in part Alain Rook, MD The University of Texas by Big Bill’s NYPD. Lawrence Lum, MD * University of Pennsylvania M.D. Anderson Cancer Center Wayne State University 53 Dr. Janet Rowley is funded in part Joseph Rosenblatt, MD Andrew Zannettino, PhD * by the Dr. Scholl Foundation. Nadim Mahmud, MD, PhD * University of Miami Institute of Medical and 54 Dr. Kathleen Sakamoto is funded University of Illinois Veterinary Science in part by Parents Against Leukemia. Janet Rowley, MD * 53 Kenneth Meehan, MD The University of Chicago Muxiang Zhou, MD 58 55 Dr. John Timmerman is fully funded Dartmouth-Hitchcock Medical Center Emory University by the Mary D. Averbrook Memorial Kathleen Sakamoto, MD 54 Research Fellow. * * Ari Melnick, MD University of California, Los Angeles Patrick Zweidler-McKay, MD, PhD 56 Dr. Benjamin Tycko is funded in part by Weill Medical College The University of Texas the Douglas Kroll Research Foundation. of Cornell University Felipe Samaniego, MD, MPH * M.D. Anderson Cancer Center The University of Texas 57 Dr. David Williams is funded in part David Miklos, MD, PhD * M.D. Anderson Cancer Center by The Marge & Charles J. Schott Foundation. Stanford University Barbara Savoldo, MD 58 Dr. Muxiang Zhou is funded in part Beverly S. Mitchell, MD Baylor College of Medicine by Clyde and Rosie Billman. Stanford University Aaron Schimmer, MD, PhD * Ramzi Mohammad, PhD University Health Network, * Newly awarded or renewed grants Wayne State University University of Toronto in ﬁ scal year 2009.

Jeffrey Molldrem, MD 49 Motomu Shimaoka, MD, PhD * The University of Texas CBR Institute for Biomedical M.D. Anderson Cancer Center Research, Inc.

Malcolm Moore, PhD Margaret Shipp, MD Memorial Sloan-Kettering Dana-Farber Cancer Institute Cancer Center Alexander Stewart, MD * Sherie Morrison, PhD 50 Mayo Clinic and Foundation Research University of California, Los Angeles Samuel Strober, MD * Markus Muschen, MD * Stanford University PORTFOLIOS Childrens Hospital Los Angeles Ana Tari, PhD LLS Research Portfolios are groups of research projects organized around a specifi c Owen O’Connor, MD, PhD * The University of Texas blood cancer interest. The list below includes donors that generously invested in a specifi c Columbia University M.D. Anderson Cancer Center LLS research portfolio during the fi scal year. Vivian Oehler, MD John Timmerman, MD 55 ALL Portfolio Myeloma and Waldenstrom Fred Hutchinson Cancer University of California, Los Angeles Macroglobulinemia Portfolio Research Center Family and Friends of Alex Katz Benjamin Tycko, MD, PhD 56 Team Endeavor Deborah Flanagan Craig Okada, MD, PhD Columbia University Portland Veterans Affairs Susan and Francis X. Reinhardt Aggressive NHL Portfolio Medical Center Andrea Velardi, MD J.B. Fuqua Foundation Università di Perugia AML Portfolio Robert Orlowski, MD, PhD 51 The University of Texas Amit Verma, MD * Friends of Jeff Sachs Campaign Indolent NHL Portfolio M.D. Anderson Cancer Center Albert Einstein College of Medicine Pat and Jeff Sachs Cheryl Chapman

Lawrence Panasci, MD Shaomeng Wang, PhD Clyde S. McGregor, Jerry and Lois Rosenblum Lady Davis Institute University of Michigan In Memory of Joan Kowing McGregor for Medical Research The Shimkin Foundation Pediatric Portfolio * Mariusz Wasik, MD Lisa and Brian Bee – Spin 4 the Cure Roger Pearse, MD, PhD University of Pennsylvania Weill Medical College CLL Portfolio Lynn and Charles Tighe of Cornell University J. Brice Weinberg, MD Stephen and Madeline Anbinder Sigma Phi Gamma Duke University Medical Center Angel Pellicer, MD, PhD CML Portfolio New York University David Williams, MD 57 Children’s Hospital Boston Rick and Debby Cox Leonidas Platanias, MD, PhD * Northwestern University

0814172_14_36-02.indd 20 11/20/08 5:26:09 PM 0814172_14_36-02.indd 21 Research Building The BuntingBlausteinCancer Judith E. Karp, MD American Technical Coatings,Inc. Charles F. Inglefield Dana-Farber CancerInstitute James Griffin, MD Karp FamilyResearch Laboratories Harvard StemCellInstitute Dana-Farber/Harvard CancerCenter Howard HughesMedicalInstitute Harvard MedicalSchool D. Gilliland, Gary MD, PhD School ofMedicine University ofPennsylvania Alan M. Gewirtz, MD Cancer Institute Oregon Health & Science University Howard HughesMedicalInstitute Brian Druker, MD Human GenomeSciences,Inc. James H. Davis, PhD, JD M.D. AndersonCancerCenter The University of Texas Jorge E. Cortes, MD Cancer Center Johns HopkinsComprehensive Curt I. Civin, MD of CornellUniversity Weill MedicalCollege Selina Chen-Kiang, PhD National InstitutesofHealth David Bodine, PhD Research Center Fred HutchinsonCancer Irwin Bernstein, MD Dana-Farber CancerInstitute Margaret A. Shipp, MD• Princess Margaret Hospital Armand Keating, MD•Chair ADVISORS Medical andScientific Vice Chair Vice Chair Treatment Center Cancer Research and University of New Mexico Cheryl L. Willman, MD Securities Bernard L.MadoffInvestment Charles Wiener Huntsman CancerInstitute School of Medicine University of Utah Guido J. Tricot, MD, PhD Dartmouth MedicalSchool Nancy Speck, PhD of Medicine Tufts University School Naomi Rosenberg, PhD Cancer Center Robert H. Lurie Comprehensive Steven T. Rosen, MD Medical Center Long Island Jewish Kanti R. Rai, MD Research Institute Abramson FamilyCancer Warren S. Pear, MD, PhD Research Center Stanford UniversityCancer Beverly S. Mitchell, MD Shands CancerCenter University ofFlorida W. Stratford May, Jr., MD, PhD Velcura Therapeutics,Inc. Michael W. Long, PhD

Research Building The BuntingBlausteinCancer Judith E. Karp, MD Dana-Farber CancerInstitute James Grifﬁn, MD Cancer Institute Oregon Health & Science University Howard Hughes Medical Institute Brian Druker, MD of CornellUniversity Weill MedicalCollege Selina Chen-Kiang, PhD Research Center Fred HutchinsonCancer Irwin Bernstein, MD•Chair The UFCWEndowment Fund The UFCW(Canada)Endowment Fund Reich Endowment Fund Vrushali Ranadive Fellowship Fund The RaeEndowment Fund Jane Elissa/CharlotteMeyers Research Fund The RachelKudish Fund Jim JacobsLeukemia Research Fund GlaxoSmithKline Foundation andGlaxoSmithKline, Inc. Research Fund Thomas M. Ford MemorialFund de Villiers Endowment Fund The Virginia Major Brooks Memorial Endowment Fund Bronstein &Robert MemorialFund Mary The BillBeattieMemorialEndowment Fund SUBCOMMITTEE Professional Education Endowment FUNDS Dana-Farber CancerInstitute Margaret A. Shipp, MD Research Center Stanford UniversityCancer Beverly S. Mitchell, MD Velcura Therapeutics,Inc. Michael W. Long, PhD 11/20/08 5:26:09 PM

The Leukemia & Lymphoma Society 21 DONORS

The below listing is made up of individuals, The Pamela B. Katten Memorial Citrix Greater Milwaukee Foundation’s foundations and corporations that Leukemia Research Foundation Tracy and Frank Collins * Elsa Schoeneich Medical generously supported LLS’s mission * Research Fund Isobel and Sydney Kemper Community Health Charities during this fi scal year. Douglas Kroll Research Foundation * of Wisconsin The Victor E. & Caroline E. Schutte Foundation Laborers’ Charitable Foundation Consolidated Carpet Chairman’s Circle Sigma Alpha Epsilon Fraternity, The Mario Lemieux Foundation Tim and Maura Costello 22 $1,000,000 and above University of Georgia Lighthouse Investment Partners, LLC Crescent Resources Burlington Coat Factory Elaine Smith Rush Limbaugh Cricket Communications Celgene Corporation Erika Steiner The Mansbach Foundation, Inc. CW33 Kids Fund, a Fund Genentech, Inc. Dr. Peter and Sandra Stern * Mapco Express of the McCormick Foundation KGO Newstalk AM 810 SunTrust Private Wealth Management Clyde S. McGregor – In Memory Cora and John H. Davis Foundation * Sunsail Novartis Pharmaceuticals, Inc. of Joan Kowing McGregor Lawrence J. and Florence A. Swing For A Cure The Orokawa Foundation Mercedes-Benz De George Charitable Trust * Taft Foundation The Joseph C. Sanfi lippo Memorial Fund The Edward L. Milstein Foundation * Don DeWaay The TBD Foundation United Food & Commercial Workers Nike Dominick’s Union (UFCW) Team Endeavor NRG Energy, Inc. Eisai, Inc. United Food & Commercial Workers Susan and Rick Theder – The Olive Garden Italian Restaurant Eli Lilly and Company Union of Canada Cure Kids Cancer Golf P.F. Chang’s China Bistro Enzon Pharmaceuticals Anonymous (1) Toyota Motor North America, Inc. PowerBar E. P. Vaughan Benefi ciaries, U.S. Bank Private Client Group TVS President’s Circle PricewaterhouseCoopers, LLP Evernham Motorsports Valassis $500,000 – $999,999 Rabobank Dr. Ralph and Marian Falk Medical Waddell & Reed, Inc. Regence BlueCross BlueShield * Mary D. Averbrook Memorial Research Trust Wilson Farms Research Fellow The Rhubard Jones Celebrity Deborah Flanagan Cephalon Oncology Golf Tournament The Simon C. Fireman Friends Runner’s World Citigroup Charitable Foundation * $10,000 – $49,999 * Pat and Jeff Sachs * Susan Lang Foundation GlaxoSmithKline Abbott Laboratories The Marge & Charles J. Schott Lehman Brothers GlaxoSmithKline Foundation Abramson Family Foundation Foundation * Millennium: The Takeda Oncology Greene Team Accenture Company Siemens Hargrove Ann Adams Seagate Technology Douglas and Phyllis Smith Peter Harman Adeler Jewelers WCCO Radio St. Valentine’s Day Luncheon and Style Show Betty Ruth and Milton Hollander ADT The Harry and Jeanette Weinberg * Diana and George Holway Foundation, Inc. * Joseph S. and Diane H. Steinberg Aegon Transamerica Foundation Team Friends of Heroes, H&R Block The Aetna Foundation Benefactors Honoring Pediatric Heroes IEP/MPG Affi liated Computer Services, Inc. $100,000 – $499,999 The Watkins Family Irving Family Fund Agility HR * American Airlines The Wayne & Gladys Valley Foundation The Jim Jacobs Charitable Foundation Ahold Financial Services Vistar Karyn Research Fund * The AK Steel Foundation Amgen, Inc. WCNN 680 The Fan Mark and Christine Kraemer, Alabama Power Company Austaco, Inc. WYAY EAGLE 106.7 FM and Charles and Lynda Kraemer Alcott Insurance Robert and JoAnna Behl Anonymous (1) The Kroger Company John W. Alden Trust Big Steaks Management, LLC KRON 4 Allen & Company, LLC Biogen Idec, Inc. Patrons Local 148 Operating Engineers * Alliance Holdings, Inc. The Stephen Birnbaum Foundation $50,000 – $99,999 Lunardi’s Supermarket, Inc. The Alson Foundation The Blackstone Group Air Products Lukas Lundin American Plant BMC West Alion Science and Technology M&T Bank American Systems Corporation Bost Custom Homes The Altschul Foundation/ The Madoff Family John Andrews Bristol-Myers Squibb Company Reichman Memorial * Tom Marano ARAMARK Peter Burg Memorial Research Fund American Electric Power * Jeffrey and Katina Mayer Arizona Cardinals Carter’s, Inc. Stephen and Madeline Anbinder Marion Superior Court Arizona Public Service Centers for Disease Control Ham Ansley Memorial Research Fund Michael McCarthy Foundation and Prevention* Asbestos Workers International Anthem BlueCross Sean and Erin McGould Insulator’s Health Hazard Fund CISCO Systems/NEC Apache Corporation Mount Gay Rum AstraZeneca Citi Patricia Armstrong New York State Department AT&T The Coleman Foundation Bahia Corinthian Yacht Club of Health, In Honor of Atlantic Skyline Community Health Charities Bank of America Senator Carl L. Marcellino of New England AutoTrader.com Hildegarde D. Becher Foundation, Inc. North Sails Dana West Yacht Club BAE Systems John and Frances Beck Family Parents Against Leukemia The John & Shirley Davies Foundation * Baker Botts, LLP Foundation Quest Diagnostics, Inc. DialAmerica Marketing Stephen Baldelli Greg and Michelle Becker Racing for a Reason F.M. Kirby Foundation * The Bank of New York Lisa and Brian Bee – Spin 4 the Cure Ruby’s Diner Genzyme Corporation Bank of Tokyo – Mitsubishi, UFJ Booz Allen Hamilton Sabre Holdings Georgia Pest Control Association Mike and Susie Barnett Ron Bradley Safeway, Inc. Jonathan Plutzik & Lesley Goldwasser The Barrett Family Foundation In Memory of Emerson B. Bridges Sailing World Family Foundation * Dorothy Baser CA, Inc. Terri Sanders Golf Tournament The Jeff Gordon Foundation John Bashta The Classic Catering People

0814172_14_36-02.indd 22 11/20/08 5:26:10 PM 0814172_14_36-02.indd 23 Capitol Federal Savings Capital Group Services, Inc. Capital Automotive Real Estate Campbell &Company Cadence DesignSystems Charlene Byrd –Houston, +Partners Bury Inc. Burson-Marsteller BTB Fitness BT Kobe and Vanessa Bryant Richard Browne Stanley Brown Foundation The Brown Family Broward Health Family Foundation Frank G. and Frieda K. Brotz Broadcom Corporation The Broad Foundation Brinks, Inc. Brewers ofIndianaGuild, Inc. The Breeden-Adams Foundation Alan Brayton Helen BrachFoundation Bowen EngineeringCorporation The BostonConsultingGroup Steve andLisaBoom Bombardier Learjet Herman &EmmieBoldenFoundation Leukemia Society Alex Boisclair Memorial Marco and Andrea Boerries The BoeingCompany Bobby &Steve’s Auto World Foundation Edward andSusanBlumenfeld BlueCross BlueShieldofMississippi BlueCross BlueShieldof Alabama The BlackieFoundation Alexandra Mayes Birnbaum BioMed Realty Trust BIO Clyde andRosieBillman Big Bite, Inc. Big Bill’s NYPD Alice Ann Bien Memorial BHP Copper, Inc. Foundation Berry Bertrand Smith&Co.Bert Berwind Corporation Jay Bernstein The BillBernbachFoundation J. Thomas Bernard Matthew Bergman John andLynn Beck Benchmark Bank Bell Family Foundation William andDebbieBehnke Beers +Cutler Beerman Foundation BearingPoint Bath Fitter Bass Pro Shops Bill BassFoundation Costco Wholesale FinanceCorporation(CFC) National RuralUtilitiesCooperative Core MedicalGroup ElectricServices,Contemporary Inc. Consumer Electronics Association Alverin M. CornellFoundation Don andRobyn Conlon The ComstockFoundation Comstock Homebuilding Compass Bank ofNew York Community Health Charities Community HealthCharitiesofIowa Community HealthCharitiesofIllinois Community HealthCharitiesofGeorgia Community HealthCharitiesof Arizona Commonwealth ofPennsylvania Commerce Bank ComEd Comcast Foundation, Inc. Columns Resource Group ofBabylon, Inc. Columbian Home Association Collins Builders Colleran, O’Hara&Mills, LLP Cole Design Co Co. Sala Calvin Clyde Clif BarFamily Foundation Christopher Clemente Bruce andIsobelCleland Clark Construction Clarence Brooks Foundation Citi SmithBarney Cintas CIBC World Market Corp. Children’s Mercy Hospital Chiaramonte ConstructionCompany Chevron Chester CountyCommunity David andRhodaChase Charles SchwabCharitableFund Charles Schwab Charity BeginsatHome Chapman Cheryl Rob andShikhaChandra Richard Jr. andCarolyn Chace CGI Cerner Corporation Central Valley Cycling CentiMark Corporation OHSU Center for HematologicMalignancies– Cells for Cells CB Richard Ellis Development, Inc. Catalfumo Construction& Casino Arizona Thomas and FoundationAgnes Carvel BloodCareCarter Don andLindaCarter Carla’s Champions Capstone Group Advisory Capitol FileMagazine Rick andDebby Cox Meredith Cowden Foundation James F. Egan EFW, Inc. Easterns Automotive Group East Bay Community Foundation Dyer Family Foundation Duquesne Light Duffy MechanicalCorporation L. F. DriscollCompany Drescher Corp. D.R.A. Properties, LC–Dennis Albaugh Dr.Scholl Foundation Dominion Mechanical Dominion Foundation Dominion D DJO, LLC The DietzeConstructionGroup Dickstein Shapiro, LLP The Devine Family Foundation andReneeDeVinck Robert Deutsche Bank 56,Department Inc. Deloitte Delaware Community Foundation Dedicated Logistics, Inc. andRitaDeCaprio Albert Deans KnightCapital ManagementLtd. DC Rental Davis Polk & Wardwell Kelvin Davis andRachelBrewster Donald andLeonaDavis John andJudy Darvish DARCARS Danya International Danford Foundation Danaher Corporation Dallas StarsFoundation Dallas Auction Gallery Cypress Semiconductor CW18 andMY24 Cumberland PackingCorp. Reno Cruz CharitableFoundation Cruise Industry Crowe Chizek Credit Suisse The Crean Foundation Brian Falbo Fairfax GlassCo. Elizabeth Fago Exotech, Inc. Exelixis, Inc. Jose andDeniseEvans Ernst & Young, LLP Enterprise Rent-A-Car Enterprise Information Management Enrichment Foundation CancerInstitute Emory University, Winship Emerson Motor Technologies Elliott Bay Marina, Inc. Electronic DataSystemsCorporation Steven Eisenstadt James L. Eichberg Foundation MAN Hero’s * * James andKaren Finkel Michael C. Fina Figg Engineering Fields Auto Group Fidelity & Trust Mark ZurackandKathy Ferguson Fenway Partners, Inc. FedEx Ofﬁ ce Federated Investors, Inc. Kevin Fay Richard J. Fasenmyer Foundation Paul andSusanFriedman Friedman, Billings, Ramsey Group, Inc. Frazier &Deeter FranklinFoundationJohn andMary FoxKiser Four Peaks Brewery Company, Inc. For Julie Foundation, Inc. FootWorks Miami Florida Hospital Florescue Foundation Florentine Camenisch Trust andGwenArt Flaming Fitzgerald Family Foundation Fish &Richardson, PC National Bank ofNew York FirstAmerican Title InsuranceCompany Allan andSherri Goldman GoldenTree Asset Management The Gold-DiggersInc. Harvey andMarianne Gold Daniel Gold GMC Michael Glover BetoKids Glory Global Traveler Magazine The Glenlivet Glembocki Family Trust Dan GleasonMemorialResearch Fund Rob andCoriGlaser Gila River Casinos Charles Gibbs,Jr. Giant Food Stores, LLC Tony andUnaGiachinta Georgia Pest Control Association General Motors The GeneralElectricFoundation Technology General DynamicsInformation General Dynamics GEICO GE Commercial Finance Chris Gautreau Gas America CharitableFoundation Ken Gardiner MedicineOrthopaedics G&T Sports Gap, Inc. KnightGaines FoundationCourtney J.B. FuquaFoundation Mrs. Dorothy C. Fuqua The Fred O. FunkhouserFoundation Fulbright &Jaworski, LLP FTI Consulting Paul N. Frimmer, Esq. * * * 11/20/08 5:26:10 PM

The Leukemia & Lymphoma Society 23 DONORS (CONTINUED)

Goldman Sachs & Co. Alan and Cledith Jennings Levon Graphics Mighty Taco Gerry Golub Jewish Community Center of Houston Lexus of Palm Beach Jeff and Kristi Miller Mark Grace Foundation JFK Medical Center Foundation Steven Lieblich Ms. Suzy Minkoff Greater Washington Sports Alliance Jim Koons Automotive Companies LifeSource The Jan Mitchell Family Foundation Greenberg Traurig, LLP Johnson & Johnson Lighthouse Marketing, Inc. The Jo Mitchell Foundation 24 The Greenbrier Companies Johnson & Johnson Health Care Linebarger Goggan Blair & Sampson Mizuho Corporate Bank Emily Griffi n Systems, Inc. Lincoln-Mercury Modern Amusement Dawson Grimsley Johnson & Johnson Matching Gifts Burton O. Lisman Trust Lori Mody Program Dr. Thomas Hahm and List Innovations Solutions The Mody Foundation Violet M. Johnson Family Foundation Kendra Christmas LLS Researchers Team Samuel Molinaro Ralph and Sally Jones Bill and Karen Hamlin Victor and Kathy Loehrer Mona Electric Roy and Peggy Jones George & Mary Josephine Donna Loren Jack Moore Memorial Golf Tournament Hamman Foundation John R. Jones, III Lowndes, Drosdick, Doster, Leroi Moore The Handlery Foundation Jones Day Kantor and Reed Morgan Franklin The Hanford Family Jones Geisler, LLP Lucasfi lm Foundation Jim and Barbara Morrison Eliyahou Harari Journal Broadcast Group Tom Luglio Kelly Marie Moulton Foundation Harford United Charities, Inc. Journal Communications, Inc. Larry and Kathi Luke Tim Murphy Harrah’s St. Louis Casino & Hotel JPMorgan Chase Ian Lundin Names Family Foundation The Harry Lee Community K-Designers Lunds and Byerly’s National Baseball Hall of Fame Service Foundation Kaelin Family Captain’s Cup The Pat Lyons Foundation National City Bank The Jason Hartman Foundation Mr. Gerald Kafka and Ms. Rita Cavanaugh Alex and Steve Lytle National Cooperative Services Richard and Julie Healey The Karches Foundation MacCutcheon Family Foundation Corporation Hefren-Tillotson, Inc. Family and Friends of Alex Katz Mackenzie Partners, Inc. Navigant Consulting Heidrick & Struggles KCE Structural Engineers Macquarie Bank Limited NDI of Maryland Heineken Christopher Kearns The Macy’s Foundation The Neiman Marcus Group Hekler-Herman Family Charitable Fund John Kellenyi Bernard L. Madoff Investment The Netter Foundation The Helis Foundation Doug Kenny Securities, LLC Bonni and Kenneth Newton The Hendin Family Kenyon & Kenyon, LLP Magnetar Capital, LLC The New York Community Trust Highmark BlueShield Ketel One, Nolet Spirits Major League Baseball The New York Mets Highmark BlueCross BlueShield KeyBanc Capital Markets, Inc. Makar Management, LLC Nicholas Family Foundation Hitt Contracting, Inc. * KeyBank Samuel P. Mandell Foundation Michael and Elin Nierenberg and Family * Hochfelder Foundation KGA Architecture Lesley Mansford Nimnicht Chevrolet Freddie Hoffman King & Spalding, LLC David Markert Ray Nixon Hogan & Hartson, LLP The Klein Family Foundation, Inc. Dario O. Marquez, Jr. Guy and Linda Nohra Holland & Knight Kohl’s Stores No. 675 and 756 Marsh, Inc. William and Elaine Nolan Holt Lunsford Commercial Bob and Sandy Kolitz Frank Marshall Mary Jane Noone Real Estate, Inc. Robert Koltun Bill Martin Northrop Grumman The Horizon Foundation for New Jersey Paul Konigsberg The Martinsville Area Community Northrop Grumman IT Hos Bros. Construction, Inc. Foundation Aaron Konstam Northwestern Mutual House of Forgings, Inc. Jack C. Massey Foundation Korum For Kids Foundation Northwestern Mutual Foundation, Inc. HP Mayo Foundation KPMG, LLP Norton Healthcare HSBC Securities (USA) Inc. McCracken Foundation Kramer Levin Naftalis & Frankel, LLP NRG HSBC Bank USA John McCray Kritchman Family Foundation The Ohio State University Hughes Hubbard The Krutz Foundation The Laffey McHugh Foundation Comprehensive Cancer Center – Hubbell Homes KST Data, Inc. McKee Nelson, LLP James Cancer Hospital and J.L. and Sydney Huffi nes Solove Research Institute Chuck and Kris Kusak McKenna, Long & Aldridge Human Genome Sciences, Inc. Olson Advertising Mike and Kathy Ladra McKesson HBOC Foundation, Inc. Mike Hunter’s Team Oncology Hematology West Lakefront Communications, Inc. McKinsey & Company, Inc. Huron Consulting Group Oncology Therapeutics Network Marie Lamfrom Charitable Foundation The McNichols Family Foundation IBM Oncore Construction Landmark 24 M.D. Anderson Cancer Center ICAP Services North America The W. O’Neil Foundation Landmark Aviation MDC Holdings/Richmond American Illinois Police Federation, Inc. Homes Oracle Corporation LandRover Dallas Independent Health Medical Mutual of Ohio Orion IP, LLC Latham & Watkins, LLP Industrial Alliance Pacifi c MedImmune, Inc. The Osprey Foundation of Maryland Jonathan and Jeannie Lavine and Family * Life Insurance Company MedStar Health Shakutala Palta L.E. Simmons & Associates, Inc. Inglett & Stubbs Memorial Healthcare System Park Place Motorcars Dallas The Lebensfeld Foundation Inland Truck Parts Company Merck & Co., Inc. Parks Palmer Turner Yemenidjian, LLP Gregory and Nancy Ledford Intel Mercy Vascular Center Party with a Purpose Cliff and Kristen Lee Intercontinental Hotel Group Meredith Corporation Foundation Paul, Hastings, Janofsky & Walker, LLP Ms. Kelli Leffi ngwell and ITG Investment Technology Group The Tony Leffi ngwell Foundation Merrill Lynch Dee Ann Payne Jack’s Mannequin Lehman Brothers Foundation Met-Rx Engineered Nutrition Peet’s Coffee & Tea JDP Mechanical Lehman Motors Daniel Metzger Penn Treaty Jeff Warrick Poultry Days Jeffrey Leiserowitz MGI Pharma PEO Experts Ultimate Classic LeMont Restaurant Microsoft Peoples Health Jeffries & Company, Inc. The Annette M. and Theodore N. Lerner Midfi rst Bank Pepco Jeffrey’s Journey Family Foundation Roberto and Allison Mignone Pepsi-Cola Company

0814172_14_36-02.indd 24 11/20/08 5:26:11 PM 0814172_14_36-02.indd 25 Transplant Program Rocky MountainBlood&Marrow MichaelEducationalInstitute Robert Riverside MedicalClinic Rio GrandeCancerFoundation Nina Richardson Rita Rich James Resnick Remillard Family Foundation Susan andFrancisX. Reinhardt andOncology Regional Consultants in Hematology Regency Commercial Construction Mr. andMrs. John Reedy Real RehabPhysical Therapy RBC Capital Markets Raytheon RayStuart Raley’s Ratopia Rand EdgarInvestment Corp. W.S. Radgowski Radcliffe Foundations Howard andCindyRachofsky Quality Food Centers, Inc. Puyallup Tribe ofIndians Pulse EFT Association, LP Provident Bank Providence HealthSystem Providence Alaska MedicalCenter Protiviti Pro-Air Price Modern, LLC Premier Foods Pray Family Foundation Dr.Antonio Prats Prairie Meadows Racetrack&Casino Prairie Farms Powell ElectricalSystems, Inc. Donald Porteous Bill andSandraPomeroy Polo RalphLauren Foundation Friends ofLigonier Polo Tournament Polly HatcherMemorialGolf PNC PMSLIC Plumbers &Pipefi tters, LocalUnion72 Plantex USA Planned SystemsInternational Jason andRenaPilalas Debbie Pilalas Maureen and Todd Pierce PhRMA Philips Phi GammaDeltaFraternity Pharmion PGT Trucking, Inc. PGA TOUR Superstores Pfi zer Petersen Aluminum Corporation Perrimeister Golf Perkins+Will Scott and Whitney Perkins Kelly andLily Perkins * Skate For Kate Jim andMarilyn Simons LeomaSimonFoundation The Sidney, Miltonand Rochelle Simms Siller &Cohen Silicon Valley Community Foundation Sidley Austin, LLP William Shively The ShimkinFoundation Ross Sherwood Shenstone Farm Renee andStanley Shapiro Carl &RuthShapiro Family Foundation Charles Shadow Carl Sewell William Sefton The ScottsMiracleGro Company Scott Health&Safety Scotia Capital Scopus Asset Management, LLC Schwinn The EdithM. Schweckendieck Trusts Foundation The Victor E. andCaroline E. Schutte Susan andMichaelSchuldes Schnucks Lee andLaurieSchneider The Schley &LangKnightFoundation Diane Schill Schiffrin, Barroway, Topaz &Kessler, LLP Scarpa Foundation Charitable Sarver Trust SAP Sanofi -Aventis U.S., Inc. Annunziata SanguinettiFoundation SanDisk CorporationFund Cornelius Sandahl The SanFranciscoFoundation San Diego Yacht Club Community Salt River Pima–MaricopaIndian John Salata SallieMae Friends ofJeff SachsCampaign Sabin MetalCorporation R/W Specialties Rural Telephone FinanceCooperative The Ruby RestaurantGroup Paul &Joan RubschlagerFoundation RREEF RR Donnelley Royals CharitiesFund–GlassFamily Royal MarineInsuranceGroup Royal BankofScotland Fred andBerniceRowan InternationalDistrict5170 Rotary Insurance Montgomery Hoffman Rossman Hurt Rosenthal Properties, LLC Jerry andLoisRosenblum Mark Rosen Richard andNancyRogers Michael Rogers ofEdgar A. Robinson Ruth RobinsonandFamily Daniel andCarol Spina John W. &Effi e E. SpeasMemorial Trust Southwest Bank Southern Company Southern California GasCompany &Oncology Southeast NebraskaHematology Sony DADC Gloria Somerville Wagner Software Performance Systems, Inc. Sodexho CorporateServices Kevin Sneader Smurfi t-Stone ContainerEnterprises, Smith Production, Inc. Smith PachterMcWhorter,PLC Smigel, Anderson&Sacks, LLP Margaret Sloan Skyy Vodka Skybridge Capital J. T. Tai &Co. Foundation, Inc. The T-System Symbol Technologies, Inc. Anne Swift Swanson Group Ltd. and Robert Amy Swan Jack and Amie Swan Dr. Matthew Sutter Sunesis Pharmaceuticals, Inc. SunTrust Bank Sun Capital Partners Summit Chalet Summit CancerCare Diane Summers Anthony andHesterSullivan Suffolk Construction Structure Tone, Inc. Strook, Strook &Lavan Linda Stover Carl Stover Foundation The MelStottlemyre Myeloma Stone Hill Winery Stinson Morrison Hecker, LLP Sterne, Kessler, Goldstein&Fox, PLLC Debra Stephen Doug SteeleGolfFore Life Tournament The SusanBlockStearnsRev. Trust STANY Foundation, Inc. Stanek Constructors, Inc. St. Vincent dePaulFoundation, Inc. St. Luke’s Hospital St. Joseph’s/Candler Sprint NY SportsNet Mark andCarol Spisak Texas Oncology, P.A. Tesoro Corporation Tenet Healthcare Foundation Tecumseh Foundation Team Briksten Kevin and Angela Taylor Target Thomas H. Tanner Family Foundation Ping Y. Tai Foundation * * Inc. Washington Convention Center Washington BusinessJournal DodgeDealers Washington Area Chrysler-Jeep- WASH FM Mike andCharlya Ward Walton Construction WAMU Wal-Mart Foundation Mrs. DwaneL. Wallace Stephanie Walker Fund Wakefi eld Capital, LLC Donald and Anna Waite Waddell &ReedKansasCityMarathon Wachovia Wealth Management Wachovia Securities Wachovia InsuranceServices W.E. Bowers Vredenburg Foundation Dr. BruceandMolly Vollmer Virginia SheldonJerome Foundation Virginia MasonMedicalCenter Vion Pharmaceutical Vineman, Inc. Verizon Vanguard Short-Term U.S. SteelCorporation UPMC HealthPlan University ofPittsburghMedicalCenter University HospitalsHealthSystem Account United Way SpecialDistribution United WayWisconsin of Pennsylvania United Way of Southeastern Unica Corporation UMB Bank UBS Investment Bank Twin Star Jack Turpin Turner SpecialProjects Turner Interiors–McKenna Turner Healthcare Tulalip Tribes CharitableFund Tube City, IMS Truland SystemsCorporation Ken andLisa Troutt Tricon Construction TRIB Total Media Traino’s Wine & Spirits Toyota ofBowie Toyota FinancialServices Toyota Margaret Toy Tom Burke Basketball Games TJX Companies Lynn andCharles Tighe Edgar A. Thronson Foundation, Inc. Foundation Thrivent Financialfor Lutherans ofMarjorie Thomas Roger Thomas onBehalf Michael andJacqueline Thomas Gillis andBillie Thomas &Steiner, LLP Thelen Reid Brown Raysman 11/20/08 5:26:11 PM

The Leukemia & Lymphoma Society 25 DONORS (CONTINUED)

Washington Gas Washington Post Media & Cars.com The Washington Redskins Washingtonian Waste Management 26 Watkins, Meegan, Drury & Company, LLC Top Campaign Fundraisers George W. Marget, III * Denotes multi-year pledge ‡ Watson Wyatt Worldwide Individuals who have raised more Dr. Carole Miller ‡ National Man & Woman of the Year WaWa Foundation than $50,000 or company teams Roger Mills that have raised more than $100,000 The Charles and Marion Weber David Monson to support LLS’s mission. Foundation Al Morteo Wechsler & Marisco Associates Lynda Adleta Scott Newman Weis Markets John Bacon Brooke Palmer Weitz & Luxenberg, PC Ramon Bermo Deb Rayburn Wells Fargo Bank BMC West Alexandra Rivkin Wendy’s of Michigan Wayne Bourg Robert P. Roche, Jr. ‡ West Marine Bristol-Myers Squibb Company Rush University Medical Center The Frederick & Margaret L. Burlington Coat Factory Dick Saunders Weyerhaeuser Foundation Chartese Burnett Carolyn Norton Schmalenberger WFAN Joe Caltabiano Sheila Schroeder Friends and Family of Jack Whelan Carter’s Seagate Technology Wheeler Family Charitable Foundation Cephalon Oncology Zach Sech The Whitney Foundation Citi Siemens Williams & Connolly, LLP CISCO Systems/NEC Catrina Stewart Wilmer Cutler Pickering Hale Dennis Clary Tracy Sundlun and Dorr, LLP Dan Cole Anne Swift Wilson, Sonsini, Goodrich & Rosati Compass Bank Andrea Van Dell Winston & Strawn Jen DeVos Vistar Winston Partners Elbit Systems of America, LLC Andrew Wieseneck Wipe Out Leukemia Forever Team Friends of Heroes, Travis Wilhite Foundation, Inc. Honoring Pediatric Heroes Bret Wilson Wisconsin Public Service James Galvanek, Jr. Wilson Farms WIVB-TV, Channel 4 Gail Gebhardt Winston Partners Richard and Kaye Woltman Genentech, Inc. Honore Woodside The Linda and Allen Womack Vicki Giambrone Charitable Fund Mark Yoffe, MD James Gregg The Woodlands Operating Co., LP Rosa Grimm Tom Woods Memorial Fund Brad Hayes The Brad Worley Company Peter Kelly WTOP Kiven, Kotler, Lieberman, Fox, Joffe, Wyeth Pharmaceuticals Goldschmidt & Kepes Team Charles and Dee Wyly, Jr. In Honor of Jack Woods Wyner Stokes Charitable Trust In Memory of Sheriff Harry Lee Jack and Myna Young Matt King Mr. and Mrs. Scott Zeilinger Lehman Brothers Anonymous (9) Ed Levendusky Shana Madoff Wayne Mangan Gina Manos Mapco Express

0814172_14_36-02.indd 26 11/20/08 5:26:12 PM 0814172_14_36-02.indd 27 Gay Nell Hall Anna Hall William Haagen Greetin Paul andBeryl Peggy Gowan Mark and Tina Garcia John andMargueriteGalt John Gallo Cesar Gajate Michelle Fried Bennett Fisher Virginia Faulman June Evans John Elling Don Edwards Peggy andMargaret Dupaquier Nelson Doland Melvin Dickhaut Anne Cruise Randall Clyatt Virginia Chambers Audrey Canty Mary Robert “Spider” Cantley Edward Blakely Howard Bernstein James andLynn Beck Gordon Averbrook Norman Abel thisﬁduring scal year. or includedLLSintheirestateplan bequeathed agiftover $10,000 thosewhohave Legacy Circlehonors * * * * The Legacy CIRCLE * * * * * * * * * * * * * * John Kaufmann Russell andMarshaJones Ellwood Jones andKaryn Norrene Harker Halpern Harry Dorothy Mikolaizyk Bob andKristenMihaljevic McCaul Mary Elaine K. Mars Anna Machado Douglas MacFarlane Ines Lomando Howard BruceLinden Sheila Levinson Levine Arthur Guynn andSarahKuglar Inez Koop Carol Johnson Hazel James Verna Jackson Fay Holzman Hiram D. Hoch Catherine Hildreth Anna Hildreth Charles andMildred Hesse Dan andDebbieHempy Peter Moonan Milligan Robert Ned Miller * * * * * * * * * *

* * * * * Bruce and Anne Swartz Sullivan Mary Michael Suchy Fredericka Steiner Eleanor Smith Rocco Silvestri Marion Shannon C. DarleneSchick Stanley I. Scheller Sarnow Norbert Kenneth Rutt Dennis Primeaux Mrs. Port Harry John Pini Andrew Passafaro andMary Billie SueParris Christina Parkes James andPhyllis Mooney Joel Woldman Eva Weissman * * * * * * * * * * * Deceased Anonymous(3) 11/20/08 5:26:12 PM

The Leukemia & Lymphoma Society 27 Independent Auditors’ REPORT

28 The Board of Directors The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of fi nancial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2008, and the related consolidated statements of activities, cash fl ows, and functional expenses for the year then ended. These consolidated fi nancial statements are the responsibility of the Society’s management. Our responsibility is to express an opinion on these consolidated fi nancial statements based on our audit. The prior year summarized comparative information has been derived from the Society’s 2007 consolidated fi nancial statements and, in our report dated October 24, 2007, we expressed an unqualifi ed opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the fi nancial statements are free of material misstatement. An audit includes consideration of internal control over fi nancial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society’s internal control over fi nancial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the fi nancial statements, assessing the accounting principles used and signifi cant estimates made by management, as well as evaluating the overall fi nancial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated fi nancial statements referred to above present fairly, in all material respects, the fi nancial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2008, and the changes in its net assets and its cash fl ows for the year then ended in conformity with U.S. generally accepted accounting principles.

October 20, 2008 New York, NY

0814172_14_36-02.indd 28 11/20/08 5:26:13 PM 0814172_14_36-02.indd 29 See accompanyingnotestoconsolidatedﬁnancial statements. Total liabilitiesandnetassets Total netassets Temporarily restricted Unrestricted Net assets: Total liabilities Grantspayable Deferred revenue Accountspayableandaccruedexpenses Liabilities: Liabilities andNet Assets Total assets Legaciesandcontributionsreceivable Accountsreceivable Cashandcashequivalents Assets Investments,atfairvalue Prepaid expenses and amortization of $12,069 and $10,435 Fixedassets,lessaccumulateddepreciation Permanentlyrestricted POSITION of FINANCIAL Consolidated Statement (with comparative amountsatJune30, 2007)(inthousands) The Leukemia &LymphomaSociety, Inc. •June30, 2008 (note 4)

(note 8) (note 8) (note 3)

(note 2)

2760 208,861 97,198 $ 217,640 $ 98,096 85,691 83,085 111,663 15,258 119,544 19,160 17,174 $ 20,700 $ 208,861 $ 217,640 $ 1,686 47,770 1,360 $ 36,180 $ ,0 4,711 4,321 4,807 7,167 ,4 4,656 5,148 145,717 162,978 192 8,634 11,932 ,7 2,873 3,079 160 77,245 81,670 2008 2007 11/20/08 5:26:13 PM

The Leukemia & Lymphoma Society 29 Consolidated Statement of ACTIVITIES

The Leukemia & Lymphoma Society, Inc. • Year ended June 30, 2008 (with summarized totals for the year ended June 30, 2007) (in thousands)

30 Temporarily Permanently Total Unrestricted Restricted Restricted 2008 2007 Revenue

Campaign contributions $ 282,816 $ 21,459 $ 142 $ 304,417 $ 292,036 Less direct donor beneﬁ t costs (42,541) – – (42,541) (42,455) Net campaign contributions 240,275 21,459 142 261,876 249,581 Legacies 6,137 – – 6,137 4,937 Donated services (note 1) 5,740 – – 5,740 5,051 Net interest and dividend income (note 3) 7,015 179 10 7,204 6,251 Net (decrease) increase in fair value of investments (4,983) 90 54 (4,839) 7,478 Grant refunds 966 – – 966 1,304 Net assets released from restrictions 18,430 (18,430) – – –

Total revenue 273,580 3,298 206 277,084 274,602

Expenses (note 9)

Program Services: Research 76,979 – – 76,979 69,269 Patient and community service 77,686 – – 77,686 66,844 Public health education 42,094 – – 42,094 38,379 Professional education 8,433 – – 8,433 7,931

Total program services 205,192 – – 205,192 182,423

Supporting Services: Management and general 24,942 – – 24,942 23,663 Fund raising 46,052 – – 46,052 44,180

Total supporting services 70,994 – – 70,994 67,843

Total expenses 276,186 – – 276,186 250,266

Change in net assets (2,606) 3,298 206 898 24,336 Net Assets

Beginning of year 85,691 8,634 2,873 97,198 72,862 End of year $ 83,085 $ 11,932 $ 3,079 $ 98,096 $ 97,198

See accompanying notes to consolidated ﬁ nancial statements.

0814172_14_36-02.indd 30 11/20/08 5:26:14 PM 0814172_14_36-02.indd 31 See accompanyingnotestoconsolidatedfinancial statements. Cash andcashequivalentsatendofyear Cash andcashequivalentsatbeginningofyear Net decrease incashandequivalents Permanentlyrestricted contributionscollected Cash flows from financingactivities: Salesofinvestments Purchases ofinvestments Purchases offixed assets Cash flows from investing activities: Grantspayable Deferred revenue Accountspayableandaccruedexpenses Prepaid expenses Legaciesandcontributionsreceivable Accountsreceivable Changesinoperatingassetsandliabilities: Depreciation andamortization Permanentlyrestricted revenue collected Netdecrease (increase) infairvalueofinvestments netcashprovided byoperatingactivities: Adjustmentstoreconcile thechangeinnetassetsto Changeinnetassets Cash flows from operatingactivities: FLOWSof CASH Consolidated Statement Net cashprovidedbyfinancing activities Net cashusedininvestingactivities Net cashprovidedbyoperatingactivities (with comparative amountsfor theyear endedJune30, 2007)(inthousands) The Leukemia &LymphomaSociety, Inc. • Year endedJune30, 2008 3,8 $ 47,770 50,139 $ (2,369) 36,180 47,770 $ (11,590) 142 142 (31,531) 130,598 (24,417) (1,985) (160,144) 178,276 (200,376) (2,317) 29,160 7,245 2,455 (96) 351 12,685 4,425 1,916 1,808 (1,037) 1,540 (96) (2,846) 326 1,578 (7,478) 1,825 (142) 4,839 24,336 $ 898 $ 2008

2007 (2) 2 2 11/20/08 5:26:14 PM

The Leukemia & Lymphoma Society 31 Consolidated Statement of FUNCTIONAL EXPENSES

The Leukemia & Lymphoma Society, Inc. • Year ended June 30, 2008 (with comparative totals for the year ended June 30, 2007) (in thousands)

32 Program Services Supporting Services Patient and Public Management Direct donor community health Professional and Fund Total beneﬁ t costs Research service education education Total general raising Total 2008 2007 2008 2007 Awards and grants $ 69,134 $ – $ – $ – $ 69,134 $ – $ – $ – $ 69,134 $ 65,939 $ – $ – Therapy acceleration program (note 5) 3,941 – – – 3,941 – – – 3,941 601 – – Financial aid to patients – 6,545 – – 6,545 – – – 6,545 5,890 – – Co-pay assistance – 4,560 – – 4,560 – – – 4,560 113 – – Donated services 1,036 4,704 – – 5,740 – – – 5,740 5,051 – – Salaries 1,327 30,689 15,359 4,418 51,793 8,623 9,947 18,570 70,363 64,331 – – Employee beneﬁ ts and taxes (note 6) 160 7,153 4,247 1,179 12,739 2,162 3,119 5,281 18,020 16,249 – – Occupancy 20 3,395 2,138 618 6,171 1,147 1,409 2,556 8,727 8,127 – – Insurance 9 278 193 42 522 84 162 246 768 695 – – Telephone 29 2,613 1,153 189 3,984 372 1,359 1,731 5,715 5,110 – – Travel 67 1,212 742 223 2,244 432 502 934 3,178 3,135 15,183 14,605 Printing and supplies 183 2,895 6,513 381 9,972 4,166 10,170 14,336 24,308 23,530 6,201 6,536 Equipment rentals and maintenance 14 893 580 154 1,641 286 428 714 2,355 1,982 – – Postage and shipping 89 1,091 4,347 162 5,689 2,206 7,372 9,578 15,267 15,163 – – Meetings 569 2,652 1,255 305 4,781 560 662 1,222 6,003 5,660 8,914 8,875 Professional fees 372 7,868 4,840 569 13,649 4,496 10,346 14,842 28,491 26,203 5,280 6,893 Miscellaneous 10 464 278 85 837 211 198 409 1,246 909 6,963 5,546 Depreciation and amortization 19 674 449 108 1,250 197 378 575 1,825 1,578 – – Total expenses $ 76,979 $ 77,686 $ 42,094 $ 8,433 $205,192 $ 24,942 $ 46,052 $70,994 $276,186 $250,266 $ 42,541 $ 42,455

See accompanying notes to consolidated ﬁ nancial statements.

Public Patient and Health and Community Professional Service Research Education Program Services EXPENSES 37.9% 37.5% 24.6%

0814172_14_36-02.indd 32 11/20/08 5:26:15 PM 0814172_14_36-02.indd 33 will beheldsubsequenttothefiscal year-end. Deferred revenue includesamountsreceived forspecialeventsthat the conditionshavebeensubstantially met. restrictions. Conditionalcontributionsare recognized asrevenue when and reported in the statement of activities as net assets released from temporarily restricted netassetsare reclassified tounrestricted netassets through thepassageoftimeorfulfillment ofapurposerestriction, or permanentlyrestricted revenue. When adonorrestriction ismet donor restrictions that limittheiruseare reported aseithertemporarily received orpromised unconditionally. Contributionsreceived with Contributions are recorded asrevenue, attheirfairvalue,when Contributions andDeferredRevenue as follows: characteristics havebeenclassified intothree netassetcategories of resources availabletotheSociety, fundsthathavesimilar To ensure observanceoflimitationsandrestrictions placedontheuse Net AssetClassifications in thestatementoffinancial position. and thatsuchchangescouldmateriallyaffecttheamountsreported in the values of investment securities will occur in the near term investment securities,itisatleastreasonably possiblethatchanges and credit risks.Duetothelevelofriskassociatedwithcertain securities are exposedtovariousriskssuchasinterest rate,market, The Societyinvestsinvariousinvestmentsecurities.Investment Risks andUncertainties disbursement requirements are met. Tax Act(Canada)andistherefore notsubjecttoincometaxesifcertain LLSC is registered as a charitable organization under the Income the InternalRevenueCode. qualify forthemaximumcharitablecontributiondeductionunder since the Society is publicly-supported, contributions to the Society income taxesunderInternalRevenueCodeSection501(a). Additionally, Revenue CodeSection501(c)(3)and,accordingly, isexemptfrom federal The Societyqualifies asacharitable organizationasdefi ned byInternal Tax-Exempt Status have beeneliminatedinconsolidation. significant inter-company andintra-Societyaccountstransactions and TheLeukemia&Lymphoma SocietyResearch Foundation.All affiliates, TheLeukemia&Lymphoma SocietyResearch Programs, Inc. Society ofCanada,Inc.(“LLSC”),andtheSociety’s not-for-profi t of theSocietyanditssixty-five chapters,TheLeukemia&Lymphoma the accountsofSociety, whichencompassestheHomeOffi ce The accompanying consolidated financial statements include Principles ofConsolidation the medicalcommunityandgeneralpublic. internet sites,conference callsandsymposiasponsorshipforboth educational informationaboutbloodcancersintheformofpublications, made totheSociety’s disseminating and InformationResourceCenter; to patients;answeringphonerequests forbloodcancerinformation facilitating psychosocialsupportgroups; providing financial aid The Society’s principalactivitiesinclude:awarding research grants; myeloma andimproving thequalityoflifepatientsandtheirfamilies. the causeandcure ofleukemia,lymphoma,Hodgkin’s diseaseand international not-for-profit health agency dedicated to seeking The Leukemia&Lymphoma Society, Inc.(the“Society”)isan Organization 1. OrganizationandSignificant AccountingPolicies depending uponthedonor-imposed restrictions. on thesefundsmaybeunrestricted ortemporarilyrestricted, in perpetuityandthatonlytheincomebeused.Incomeearned donor-imposed restrictions requiring thattheprincipalbeinvested Permanently restricted net assets:Consistoffundsthatcontain the fundsmustbemaintainedintactoverlifetimesofdonors. relating totermendowment ordeferred givingarrangementsinwhich by donorsforaspecifi c timeperiodorpurpose,aswellamounts Temporarily restricted netassets: Consistoffundsthatare restricted in anyofitsprograms orsupportingservices. at the discretion of the Board of Directors, for the Society to utilize Unrestricted netassets:Consistoffundsthatare fullyavailable, STATEMENTSFINANCIAL Notes toConsolidated (with comparative amountsasofandfor theyear endedJune30, 2007) The Leukemia &LymphomaSociety, Inc. •June30, 2008 of theFSP. the Societywillhavetoadoptcertain ofthedisclosure requirements if required, untilsuchtime.However, fortheyearendingJune30,2009, UPMIFA sotheSocietywillnothavetoreclassify itsnetassets, until appropriated forexpenditure. NewYork Statehasnotyetadopted permanently restricted netassetsastemporarilyrestricted netassets of adonor-restricted endowmentfundthatisnotclassifi ed as A keycomponentofthatFSPisarequirement toclassifytheportion will beeffectivefortheSociety’s fi scal yearendingJune 30,2009. for AllEndowmentFunds (FSP), was issued, and its guidance of InstitutionalFundsAct(UPMIFA) andEnhancedDisclosures Subject toanEnactedVersion oftheUniformPrudentManagement of Not-for-ProfiNet AssetClassifit Organizations: cation ofFunds In August2008,FASB StaffPositionNo.FAS 117-1,Endowments measurements onthe statementofactivities. used todevelopthefairvaluemeasurements, andtheimpactofcertain of SFAS 157willrequire additionaldisclosures regarding theinputs impact ontheSociety’s financial statements;however, theadoption 2009. TheadoptionofSFAS 157isnotexpectedtohaveamaterial SFAS 157willbeeffectivefortheSociety’s fi scal yearendingJune30, value, andrequires expandeddisclosures aboutfairvaluemeasurements. SFAS 157defi nes fairvalue,establishesaframeworkformeasuring fair Standards (SFAS) No. 157, FairValue Measurements (SFAS 157). In September 2006, the FASB issued Statement of Financial Accounting to haveamaterialeffectontheSociety’s financial statements. and penalties,disclosure. TheadoptionofFIN48isnotexpected provides related guidanceonmeasurement, classification, interest positions takenorexpectedtobeinataxreturn. FIN48also of more-likely-than-not forrecognition and derecognition oftax in anorganization’s financial statementsandprescribes athreshold addresses theaccountingforuncertaintiesinincometaxesrecognized be effectivefortheSociety’s fi scal yearendingJune30,2009.FIN48 an interpretation ofFASB StatementNo.109(FIN48),whichwill Interpretation No.48,Accounting for Uncertainty in Income Taxes – In June2006,theFinancialAccountingStandards Board (FASB) issued Recent AccountingStandards presentation. to the2007comparativeinformationconformcurrent year information was derived. Certain reclassifications have been made 2007 consolidatedfinancial statements from whichthesummarized such informationshouldberead inconjunctionwiththeSociety’s are presented intotalratherthanbyfunctional category. Accordingly, in thestatementoffunctionalexpenses,2007expensesbyobject such prioryearinformationisnotpresented bynetassetclassand, comparative information.With respect tothestatementofactivities, The financial statementsare presented with2007summarizedor Summarized FinancialInformation differ from thoseestimates. in thefinancial statementsandaccompanying notes.Actualresults could to makeestimatesandassumptionsthataffecttheamountsreported accepted accountingprinciplesrequires theSociety’s management The preparation offi nancial statementsinconformitywithgenerally Estimates lives oftheassetsortermsleases,ifshorter. amortized usingthestraight-linemethodoverestimateduseful value atdateofdonation,ifcontributed,andare depreciated or leasehold improvements, are recorded atcost,ifpurchased, oratfair Fixed assets,whichconsistprincipallyofequipment,software, and Fixed AssetsandDepreciation for long-termpurposesreported asinvestments. of three monthsorlessfrom dateofpurchase, exceptforamountsheld Cash equivalents consist of short-term investments with a maturity Cash Equivalents revenue andexpense. and research grantreviewers havebeenvaluedandare reported asboth Specifically, thedonatedservicesoffamilysupportgroup facilitators receives meetthecriteriaforrecognition inthefi nancial statements. The Societyhasdeterminedthatcertainofthedonatedservicesit Donated Services 11/20/08 5:26:15 PM

The Leukemia & Lymphoma Society 33 Notes to Consolidated

FINANCIAL STATEMENTS (CONTINUED)

The Leukemia & Lymphoma Society, Inc. • June 30, 2008 (with comparative amounts as of and for the year ended June 30, 2007)

34 2. Legacies and Contributions Receivable 6. Pension Plan The Society’s legacies and contributions receivable at June 30, 2008 The Society has a noncontributory, defi ned contribution 403(b) and 2007 consist of unconditional promises to give and legacies pension plan covering all employees meeting age and service for which the underlying wills have been declared valid by the probate requirements. Contributions are based on a percentage of each eligible court and no other conditions are required to be met. Amounts are employee’s salary and years of service. Expense under this plan scheduled to be received as follows (in thousands): aggregated $3,780,000 and $3,133,000 for the years ended June 30, 2008 and 2007, respectively. 2008 2007 On July 1, 2006, the Society adopted a 457 Deferred Compensation Plan Less than one year $ 4,886 $ 3,197 (the “457 Plan”), for its executive staff. The 457 Plan is a nonqualifi ed 1 to 5 years 2,118 622 deferred compensation plan subject to the provisions of the Internal After 5 years 445 778 Revenue Code Section 457. Expenses under this plan approximated $134,000 and $194,000 for the years ended June 30, 2008 and 2007, 7,449 4,597 respectively. The assets and liabilities of this plan are included in Less discount to present value investments and accounts payable in the accompanying statement (discount rate – 5%) (282) (276) of fi nancial position and amounted to approximately $314,000 and $285,000 for the years ended June 30, 2008 and 2007, respectively. Total $ 7,167 $ 4,321

7. Lease Commitments 3. Investments The leases for premises which the Society’s Home Ofﬁ ce and chapters occupy expire on various dates through May 31, 2018 and provide The following is a summary of investments at June 30, 2008 for certain payments subject to escalation and periodic rate increases and 2007 (in thousands): relating to real estate taxes, operating expenses and utilities. The Home 2008 2007 Ofﬁ ce lease has been renewed through March 2016.

Cost or Cost or The approximate minimum future annual rental commitments Donated Fair Donated Fair are summarized as follows (in thousands): Value Value Value Value

Money market funds $ 939 $ 939 $ 1,419 $ 1,419 Year ending June 30: Corporate notes 2009 $ 7,689 and bonds 67,425 67,156 42,744 42,323 2010 6,814 Common stocks 2011 5,358 and mutual funds 33,057 33,301 29,072 35,395 2012 4,440 2013 2,854 Government obligations 40,532 41,199 47,409 47,186 Thereafter 5,392

Other 22,130 20,383 17,309 19,394 Total $ 32,547 Total $ 164,083 $ 162,978 $ 137,953 $ 145,717

Debt and equity securities are recorded at fair value as determined 8. Temporarily and Permanently Restricted Net Assets by quoted market prices. Mutual funds are recorded at fair value Temporarily restricted net assets and the income earned on permanently using published unit values. Other investments at June 30, 2008 restricted net assets are available for the following purposes at June 30, and 2007, consist principally of limited partnerships, the underlying 2008 and 2007 (in thousands): holdings of which are principally marketable securities. Investment 2008 2007 expenses of $416,000 and $436,000 have been netted against interest and dividend income for the years ended June 30, 2008 and 2007, Temporarily Permanently Temporarily Permanently respectively. Restricted Restricted Restricted Restricted

4. Awards and Grants Research $ 2,913 $ 3,030 $ 1,907 $ 2,825 Patient service 8,972 – 6,662 – Awards and grants for research are recognized as expense in the year approved by the Society’s Board of Directors. Multi-year grants, Other 47 49 65 48 which are generally two to ﬁ ve years in length, are approved on an Total $ 11,932 $ 3,079 $ 8,634 $ 2,873 annual basis and may be terminated at the discretion of the Society’s Board of Directors. In addition to unconditional grants payable of $81,670,000 at June 30, 2008, the Society has grant commitments 9. Joint Costs Allocation of $110,077,000 that are conditioned upon future events and, In 2008 and 2007, the Society incurred joint costs for informational accordingly, are not recorded. materials and activities that included fund raising appeals as follows (in thousands): 5. Therapy Acceleration Program (“TAP”) TAP is the Society’s new strategic initiative to speed the development 2008 2007 of blood-cancer treatments and supportive diagnostics by creating Fund raising $ 14,505 $ 14,069 business alliances with biotechnology and pharmaceutical companies. Patient and TAP provides funding for Investigational New Drug-enabling community service 1,161 1,038 (“IND-enabling”) studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are Public health education 12,243 11,652 achieved. Multiyear contracts, which are generally two to three years Total $ 27,909 26,759 in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of the Society’s Board of Directors. The Society has contract commitments of $9,500,000 at June 30, 2008 conditioned upon future events and, accordingly are not recorded.

0814172_14_36-02.indd 34 11/20/08 5:26:17 PM 0814172_14_36-02.indd 35 Chesterfield, MO Stimulys PerformanceMarketing Thomas F. Hunter Secretary/Treasurer Louisville, KY & Winslow, PSC Anderson, Bryant, Lasky Margaret H. Anderson Development Vice ChairforResource Chapel Hill, NC Marie Lauria, MSW Vice ChairforPatient Services Morristown, NJ Honeywell Paul J. Cienki Vice ChairforFieldRelations Toronto, Ontario, Canada Princess Margaret Hospital Armand Keating, MD and Scientific Affairs Vice ChairforMedical Kansas City, MO Stinson MorrisonHecker, LLP David Frantze Chair oftheBoard National LEADERS Gainesville, FL Shands CancerCenter University ofFlorida W. Stratford May, Jr., MD, PhD North Haledon, NJ Dennis F. Marco Ann Arbor, MI Velcura Therapeutics,Inc. Michael W. Long, PhD Herndon, VA NRUCFC Steven Lilly Detroit, MI Honigman MillerSchwartzandCohn John M. Kamins Cleveland, OH American Technical Coatings,Inc. Charles F. Inglefi eld Kansas City, MO Stinson MorrisonHecker, LLP Lynn C. Hoover Portland, OR The RegenceGroup Steven L. Hooker Philadelphia, PA School of Medicine University ofPennsylvania Alan M. Gewirtz, MD Purchase, NY Gellert &Klein,PC John A. Geoghegan Los Angeles,CA Irell &Manella,LLP Paul N. Frimmer Worcester, MA Saint GobainCorporation Thomas L. Fitzpatrick Dallas, TX Baker Botts,LLP Timothy Durst Rockville, MD Human GenomeSciences,Inc. James H. Davis, PhD, JD Houston, TX M.D. AndersonCancerCenter The UniversityofTexas Jorge Cortes, MD San Diego,CA Michael Copley Cincinnati, OH Vorys, Sater, Seymour&Pease,LLP Scott Carroll Twain Harte,CA Robert A. “Spider” Cantley New York, NY Peartree Communications,Inc. Alexandra Mayes Birnbaum Board ofDirectors Thomas R. Snyder New Cumberland,PA Simmonds,Mary MD Sugar Land, TX Jay L. Silver Miami, FL Norbert J. Sieber Philadelphia, PA Citrin Cooperman&Company, LLP Kevin R. Ryan Boston, MA Tufts University School of Medicine Naomi Rosenberg, PhD Palm Beach, FL JSN Consulting Jason North Detroit, MI andCohn Honigman MillerSchwartz Rodman N. Myers El Sequndo,CA Rapp Collins Worldwide James McKinnis Gold River, CA Corporation Synergex International Michele Wong New York, NY Securities,LLC Bernard L.MadoffInvestment Charles Wiener Thousand Oaks,CA Amgen Kathryn West, RN, MSN, OCN Wichita, KS ofMid-America Presbyterian Manors William M. Ward, Jr. Nashville, TN Nashville Bank and Trust STAFF Senior Patient Services Patient Services Senior Vice President Hildy Dillon Public Policy Senior Vice President George Dahlman Chief InformationOfficer Senior Vice President Jeff Como Chief FinancialOffi cer Jimmy Nangle Chief Marketing&RevenueOfficer Nancy Klein Research &MedicalPrograms Chief MedicalOfficer Barton Kamen, MD, PhD Research & Scientific Programs Chief Scientific Offi cer Louis DeGennaro, PhD President and Chief Executive Officer John E. Walter Operations General Manager Nancy Allen Chief ExecutiveOffi cer Rudy Putns Society ofCanada The Leukemia &Lymphoma Chapter Growth Senior Vice President David Timko Field Development Acting SeniorVice President George Omiros Human Resources Senior Vice President Steven Messinger 11/20/08 5:26:17 PM

The Leukemia & Lymphoma Society 35 Chapter OFFICES (ALPHABETICAL BY STATE)

Alabama Georgia Southern New Jersey/ Rhode Island Alabama/Gulf Coast Chapter Georgia Chapter Shore Region Chapter Rhode Island Chapter 100 Chase Park South • Suite 220 3715 Northside Parkway 528 B Fellowship Road 1150 Pontiac Avenue • Suite 1 Birmingham, AL 35244 Building 400 • Suite 300 Mount Laurel, NJ 08054 Cranston, RI 02920 205.989.0098 Atlanta, GA 30327 856.638.1250 401.943.8888 678.279.2001 Arizona New Mexico South Carolina Desert Mountain States Chapter Illinois New Mexico/El Paso Chapter South Carolina Chapter 36 3877 North 7th Street • Suite 300 Illinois Chapter 3411 Candelaria NE • Suite M 107 Westpark Boulevard • Suite 150 Phoenix, AZ 85014 651 West Washington Boulevard • Suite 400 Albuquerque, NM 87107 Columbus, SC 29210 602.788.8622 Chicago, IL 60661 505.872.0141 803.731.4060 312.651.7350 California New York Tennessee Central California Chapter Indiana Central New York Chapter Mid South Chapter 470 East Herndon • Suite 102 Indiana Chapter Learbury Centre 4445 Malone Road Fresno, CA 93720-2929 941 East 86th Street • Suite 100 401 North Salina Street • Suite 304 Memphis, TN 38118 559.435.1482 Indianapolis, IN 46240 Syracuse, NY 13203-1770 901.507.1634 317.726.2270 315.471.1050 Greater Los Angeles Chapter Tennessee Chapter 6033 West Century Boulevard • Suite 300 404 BNA Drive • Suite 102 Iowa Long Island Chapter Los Angeles, CA 90045 • Nashville, TN 37217 Iowa Chapter 555 Broad Hollow Road Suite 403 310.216.7600 8033 University Boulevard • Suite A Melville, NY 11747 615.331.2980 Des Moines, IA 50325 631.752.8500 Greater Sacramento Area Chapter Texas 4604 Roseville Road • Suite 100 515.270.6169 / 800.374.1074 New York City Chapter Central Texas Chapter North Highlands, CA 95660 475 Park Avenue South • 8th Floor 9211 Waterford Centre Boulevard Kansas 916.348.1793 New York, NY 10016 Suite 275 Kansas Chapter 212.448.9206 Greater San Francisco Bay Area 300 North Main • Suite 300 Austin, TX 78758 Chapter Wichita, KS 67202 Upstate New York/Vermont Chapter 512.491.6610 1390 Market Street • Suite 1200 • 316.266.4050 5 Computer Drive West Suite 100 North Texas Chapter San Francisco, CA 94102-5306 Albany, NY 12205 8111 LBJ Freeway • Suite 425 415.625.1100 Mid-America Chapter 518.438.3583 6811 West 63rd Street Dallas, TX 75251 Orange County Inland Empire Chapter Cloverleaf Building #1 • Suite 202 Westchester/Hudson Valley Chapter 972.239.0959 2020 East First Street • Suite 120 • Shawnee Mission, KS 66202-4001 1311 Mamaroneck Avenue Suite 130 South Texas Chapter Santa Ana, CA 92705 913.262.1515 White Plains, NY 10605 950 Isom Road • Suite 125 714.881.0610 914.949.0084 San Antonio, TX 78216 San Diego/Hawaii Chapter Kentucky Western New York/ 210.377.1775 9150 Chesapeake Drive • Suite 100 Kentucky and Southern Indiana Finger Lakes Chapter Texas Gulf Coast Chapter San Diego, CA 92123 Chapter 4053 Maple Road 600 East Main Street • Suite 102 5005 Mitchelldale • Suite 115 858.277.1800 Amherst, NY 14226 Louisville, KY 40202-1077 Houston, TX 77092 716.834.2578 713.680.8088 Silicon Valley and Monterey Bay 502.584.8490 Area Chapter North Carolina Virginia 675 North First Street • Suite 1100 Maryland Eastern North Carolina Chapter Virginia Chapter San Jose, CA 95112-5156 Maryland Chapter 401 Harrison Oaks Boulevard • Suite 200 11350 McCormick Road 5511 Staples Mill Road • Suite 202B 408.271.2873 Cary, NC 27513 Executive Plaza lll • Suite 100 Richmond, VA 23228 919.677.3993 804.627.0400 Colorado Hunt Valley, MD 21031 Rocky Mountain Chapter 410.527.0220 Western North Carolina Chapter 5950 Fairview Road • Suite 250 Washington 5353 West Dartmouth Avenue • Suite 400 Massachusetts Charlotte, NC 28210 Washington/Alaska Chapter Denver, CO 80227 530 Dexter Avenue North • Suite 300 303.984.2110 Massachusetts Chapter 704.998.5012 9 Erie Drive • Suite 101 Seattle, WA 98109 206.628.0777 Connecticut Natlick, MA 01760 Ohio Connecticut Chapter 508.810.1300 / 800.688.6572 Central Ohio Chapter 2225 City Gate Drive • Suite E Washington, D.C. 300 Research Parkway • Suite 310 Michigan Columbus, OH 43219 National Capital Area Chapter Meriden, CT 06450 5845 Richmond Highway • Suite 800 203.379.0445 / 888.282.9465 Michigan Chapter 614.476.7194 1421 East Twelve Mile Road • Building A Alexandria, VA 22303 Madison Heights, MI 48071 Northern Ohio Chapter 703.960.1100 Delaware 23297 Commerce Park Road 248.582.2900 Delaware Chapter Cleveland, OH 44122 Wisconsin 100 West 10th Street • Suite 209 Minnesota 216.910.1200 Wisconsin Chapter Wilmington, DE 19801 200 South Executive Drive Minnesota Chapter Southern Ohio Chapter 302.661.7300 Brookﬁ eld, WI 53005 8441 Wayzata Boulevard • Suite 340 2300 Wall Street • Suite H 262.790.4701 Florida Golden Valley, MN 55426 Cincinnati, OH 45212 Central Florida Chapter 763.545.3309 513.361.2100 3319 Maguire Boulevard • Suite 101 Orlando, FL 32803 Mississippi/Louisiana Oklahoma Canada 407.898.0733 Mississippi/Louisiana Chapter Oklahoma Chapter 3636 South 1-10 Service Road • Suite 304 500 North Broadway • Suite 250 Canada Corporate Northern Florida Chapter Metairie, LA 70001 Oklahoma City, OK 73102 804-2 Lansing Square 7077 Bonneval Road • Suite 610 504.837.0945 405.943.8888 Toronto, ON M2J 4P8 Jacksonville, FL 32216 416.661.9541 x104 904.332.6414 Missouri Oregon BC/Yukon Region, Vancouver Chapter Gateway Chapter Palm Beach Area Chapter Oregon/Southwest Washington Chapter 1682 West 7th Avenue • Suite 310 77 West Port Plaza • Suite 101 9320 SW Barbur Boulevard • Suite 140 4360 Northlake Boulevard • Suite 109 Vancouver, BC V6J 4S6 Street Louis, MO 63146-3111 Palm Beach Gardens, FL 33410 Portland, OR 97219 604.733.2873 314.878.0780 561.775.9954 503.245.9866 Ontario Region, Greater Toronto Southern Florida Chapter Nebraska Pennsylvania Area Chapter 2 Oakwood Boulevard • Suite 200 Nebraska Chapter Central Pennsylvania Chapter 480 University Avenue • Suite 1502 Hollywood, FL 33020 10832 Old Mill Road • Suite 200 800 Corporate Circle • Suite 100 Toronto, ON M5G 1V2 954.744.5300 Omaha, NE 68154 Harrisburg, PA 17110 416.585.2873 402.344.2242 717.652.6520 Southwest Florida Chapter Prairies Region, Calgary Chapter 9200 Bonita Beach Road • Suite 215 Nevada Eastern Pennsylvania Chapter 110-1202 Centre Street S.E. Bonita Springs, FL 34135 Southern Nevada Chapter 555 North Lane • Suite 5010 Calgary, AB T2G 5A5 239.992.5781 6280 South Valley View Boulevard • Suite 342 Conshohocken, PA 19428 403.263.5300 610.834.0030 Suncoast Chapter Las Vegas, NV 89118 Quebec Region, Montreal Chapter 3507 East Frontage Road • Suite 300 702.436.4220 Western Pennsylvania and 1255 University Street • Suite 1608 Tampa, FL 33607 West Virginia Chapter Montreal, QC H3B 3X2 813.963.6461 New Jersey River Walk Corporate Centre 514.875.1000 Northern New Jersey Chapter 333 East Carson Street • Suite 441 14 Commerce Drive • Suite 301 Pittsburgh, PA 15219 Cranford, NJ 07016 412.395.2873 908.956.6600

0814172_14_36-02.indd 36 11/20/08 5:26:18 PM